<html lang="en" class="pb-page js" data-request-id="94d68ba925aef18e-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d68ba925aef18e-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/OcL_nSqGW4yitGluZmDLjYR2EwCgXVtgIA9diGeHPyGtIhHZl1VE2ZPgKZ3lyAOezbXA3-8dXtW2k2yFtckUTw=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Bimekizumab versus Adalimumab in Plaque Psoriasis | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d68ba925aef18e-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.3066101403539505"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Rheumatology|Dermatology">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Rheumatology General|Psoriasis"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2102388","title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","category":"Research","type":"Original Article","topics":"Rheumatology General|Psoriasis","specialties":"Rheumatology|Dermatology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-07-08T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Rheumatology|Dermatology\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Rheumatology General|Psoriasis\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2102388","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Quick Take","title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","doi":"10.1056/NEJMdo006082","issueDate":"2021-07-08T00:00Z","age":"6Months-1990","isFree":"n","topics":"Rheumatology General|Psoriasis","viewType":"Full","specialties":"Rheumatology|Dermatology"},{"type":"Research Summary","title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","doi":"10.1056/NEJMdo006083","issueDate":"2021-07-08T00:00Z","age":"6Months-1990","isFree":"n","topics":"Rheumatology General|Psoriasis","viewType":"Full","specialties":"Rheumatology|Dermatology"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d68ba925aef18e-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Bimekizumab versus Adalimumab in Plaque Psoriasis"><meta name="dc.Creator" content="Richard B. Warren"><meta name="dc.Creator" content="Andrew Blauvelt"><meta name="dc.Creator" content="Jerry Bagel"><meta name="dc.Creator" content="Kim A. Papp"><meta name="dc.Creator" content="Paul Yamauchi"><meta name="dc.Creator" content="April Armstrong"><meta name="dc.Creator" content="Richard G. Langley"><meta name="dc.Creator" content="Veerle Vanvoorden"><meta name="dc.Creator" content="Dirk De Cuyper"><meta name="dc.Creator" content="Christopher Cioffi"><meta name="dc.Creator" content="Luke Peterson"><meta name="dc.Creator" content="Nancy Cross"><meta name="dc.Creator" content="Kristian Reich"><meta name="dc.Description" content="Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the tumor necrosis factor inhibitor ..."><meta name="Description" content="Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the tumor necrosis factor inhibitor ..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-07-08"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2102388"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202107083850207"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMoa2102383"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright Â© 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2102388">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2102388">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2102388">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Bimekizumab versus Adalimumab in Plaque Psoriasis | NEJM">
        <meta property="og:title" content="Bimekizumab versus Adalimumab in Plaque Psoriasis | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2102388">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/d986ea30-c4c8-4e55-84b1-561a5256a379/nejmoa2102388_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/d986ea30-c4c8-4e55-84b1-561a5256a379/nejmoa2102388_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A
and interleukin-17F. The efficacy and safety of bimekizumab as compared with the tumor
necrosis factor inhibitor ...">
        <meta name="twitter:description" content="Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A
and interleukin-17F. The efficacy and safety of bimekizumab as compared with the tumor
necrosis factor inhibitor ...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2102388">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2102388">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;article:article:doi\:10.1056/NEJMoa2102388;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;issue:issue:doi\:10.1056/nejm_2021.385.issue-2;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2102388" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2102388" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2102388" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2102388" class="inputDoi"><input type="hidden" value="R.B. Warren and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;385:130-141" class="inputCitation"><input type="hidden" value="04-23-2021" class="inputEPubDate"><input type="hidden" value="July 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Bimekizumab versus Adalimumab in Plaque Psoriasis" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d68ba925aef18e-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Bimekizumab versus Adalimumab in Plaque Psoriasis</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Richard B.</span> <span property="familyName">Warren</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andrew</span> <span property="familyName">Blauvelt</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jerry</span> <span property="familyName">Bagel</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kim A.</span> <span property="familyName">Papp</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9557-3642" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9557-3642</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Paul</span> <span property="familyName">Yamauchi</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">April</span> <span property="familyName">Armstrong</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Richard G.</span> <span property="familyName">Langley</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+5</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Veerle</span> <span property="familyName">Vanvoorden</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Dirk</span> <span property="familyName">De Cuyper</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christopher</span> <span property="familyName">Cioffi</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Luke</span> <span property="familyName">Peterson</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nancy</span> <span property="familyName">Cross</span>, <span property="honorificSuffix">M.D.</span></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Kristian</span> <span property="familyName">Reich</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-5</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">April 23, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">385</span></span>:<span property="pageStart">130</span>-<span property="pageEnd">141</span></div><div class="doi">DOI: 10.1056/NEJMoa2102388</div><div class="core-enumeration"><a href="/toc/nejm/385/2"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">385</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">2</span></span></a></div><div><a href="#tab-information">Copyright Â© 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRichard%2BB.%2BWarren%252C%2BAndrew%2BBlauvelt%252C%2BJerry%2BBagel%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D2%26contentID%3D10.1056%252FNEJMoa2102388%26title%3DBimekizumab%2Bversus%2BAdalimumab%2Bin%2BPlaque%2BPsoriasis%26publicationDate%3D07%252F08%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2102388" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRichard%2BB.%2BWarren%252C%2BAndrew%2BBlauvelt%252C%2BJerry%2BBagel%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D2%26contentID%3D10.1056%252FNEJMoa2102388%26title%3DBimekizumab%2Bversus%2BAdalimumab%2Bin%2BPlaque%2BPsoriasis%26publicationDate%3D07%252F08%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/fbdcca36-703a-4f7f-873b-c006af4fd90c/nejmoa2102388.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2102388.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2102388" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2102388" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2102388.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the tumor necrosis factor inhibitor adalimumab in patients with moderate-to-severe plaque psoriasis have not been extensively examined.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We randomly assigned patients with moderate-to-severe plaque psoriasis in a 1:1:1 ratio to receive subcutaneous bimekizumab at a dose of 320 mg every 4 weeks for 56 weeks; bimekizumab at a dose of 320 mg every 4 weeks for 16 weeks, then every 8 weeks for weeks 16 to 56; or subcutaneous adalimumab at a dose of 40 mg every 2 weeks for 24 weeks, followed by bimekizumab at a dose of 320 mg every 4 weeks to week 56. The primary end points were a 90% or greater reduction from baseline in the Psoriasis Area and Severity Index (PASI) score (PASI 90 response; PASI scores range from 0 to 72, with higher scores indicating worse disease) and an Investigatorâs Global Assessment (IGA) score of 0 or 1, signifying clear or almost clear skin (scores range from 0 [clear skin] to 4 [severe disease]), at week 16. The analysis of the primary end points tested noninferiority at a margin of â10 percentage points and then tested for superiority.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f0.jpg"><img src="/cms/10.1056/NEJMoa2102388/asset/d986ea30-c4c8-4e55-84b1-561a5256a379/assets/images/large/nejmoa2102388_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 614 patients were screened, and 478 were enrolled; 158 patients were assigned to receive bimekizumab every 4 weeks, 161 to receive bimekizumab every 4 weeks and then every 8 weeks, and 159 to receive adalimumab. The mean age of the patients was 44.9 years; the mean PASI score at baseline was 19.8. At week 16, a total of 275 of 319 patients (86.2%) who received bimekizumab (both dose groups combined) and 75 of 159 (47.2%) who received adalimumab had a PASI 90 response (adjusted risk difference, 39.3 percentage points; 95% confidence interval [CI], 30.9 to 47.7; P&lt;0.001 for noninferiority and superiority). A total of 272 of 319 patients (85.3%) who received bimekizumab and 91 of 159 (57.2%) who received adalimumab had an IGA score of 0 or 1 (adjusted risk difference, 28.2 percentage points; 95% CI, 19.7 to 36.7; P&lt;0.001 for noninferiority and superiority). The most common adverse events with bimekizumab were upper respiratory tract infections, oral candidiasis (predominantly mild or moderate as recorded by the investigator), hypertension, and diarrhea.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In this 56-week trial, bimekizumab was noninferior and superior to adalimumab through 16 weeks in reducing symptoms and signs of plaque psoriasis but was associated with a higher frequency of oral candidiasis and diarrhea. Longer and larger trials are required to determine the efficacy and safety of bimekizumab as compared with other agents in the treatment of plaque psoriasis. (Funded by UCB Pharma; BE SURE ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03412747" target="_blank">NCT03412747</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006082/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/0ba0189f-6e9d-4303-aba9-7e3bb0d75a9c/media/NEJMdo006082_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006082/full/" class="ng-do-media_item-title-link">Bimekizumab versus Adalimumab in Plaque Psoriasis</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 38s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">The proinflammatory cytokines interleukin-12 and tumor necrosis factor (TNF) play roles in the pathogenesis of psoriasis.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> Additional involvement of interleukin-17 and interleukin-23 in the pathogenesis of this condition has been identified; however, TNF inhibitors remain a mainstay treatment for psoriasis.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3 r4" id="body-ref-r4" href-manipulated="true">2-4</a></sup> The cytokines interleukin-17A and interleukin-17F form homodimers (interleukin-17A/17A and interleukin-17F/17F) and heterodimers (interleukin-17A/17F) and act synergistically with TNF in stimulating inflammation.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6" id="body-ref-r6" href-manipulated="true">5,6</a></sup> Some evidence suggests that interleukin-17A inhibition is superior to TNF inhibition in controlling the pathologic features of psoriasis.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7" href-manipulated="true" aria-label="Reference 7">7</a></sup> Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F, which â unlike inhibitors of interleukin-17A alone â results in the inhibition of all three dimeric isoforms, including interleukin-17F/17F.</span><sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9" id="body-ref-r9" href-manipulated="true">8,9</a></sup> Other phase 3 trials involving patients with plaque psoriasis (BE VIVID, BE READY, and BE RADIANT) have shown clinical improvements with bimekizumab as compared with placebo, the interleukin-12 and interleukin-23 inhibitor ustekinumab, or the interleukin-17A inhibitor secukinumab.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r10 r11" id="body-ref-r11-1" href-manipulated="true">8,10,11</a></sup> Here, we report results of the BE SURE phase 3 trial, which compared the efficacy and safety of bimekizumab with adalimumab in patients with plaque psoriasis. This trial also aimed to assess the maintenance of efficacy with bimekizumab when administered every 8 weeks or every 4 weeks.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">Patients were recruited through waiting-room flyers, and eligibility assessments were performed by the trial investigators. Eligible patients were 18 years of age or older, had plaque psoriasis for at least 6 months before screening, and had moderate-to-severe plaque psoriasis at screening and baseline. Moderate-to-severe plaque psoriasis was defined as a Psoriasis Area and Severity Index (PASI) score of at least 12 (range, 0 to 72, with higher scores indicating worse disease), a body-surface area affected by psoriasis of at least 10%, and an Investigatorâs Global Assessment (IGA) score of at least 3 on a 5-point scale (with 0 representing complete clearance and 4 representing severe psoriasis). Patients with previous exposure to bimekizumab or adalimumab were excluded, as were patients who had had primary failure (no response within 12 weeks) to any antiâinterleukin-17 biologic agent or to more than one biologic agent of any other class. (Full inclusion and exclusion criteria are provided in the <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org.)</div></section><section id="sec-1-2"><h3>Trial Oversight</h3><div role="paragraph">The trial was funded by UCB Pharma and designed by the ninth through the twelfth authors and UCB Pharma. UCB Pharma provided the trial drugs and conducted the statistical analyses. The second through sixth authors and the last author gathered the data. All the authors had full access to the trial data and vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol. The sponsor had no restrictions on publication of the article by the academic authors. Confidentiality agreements were in place between UCB Pharma and the authors. All the authors collaborated on writing the manuscript with the assistance of a professional medical writer funded by UCB Pharma. All the patients provided written informed consent, documented in accordance with local regulations, the Good Clinical Practice guidelines of the International Council for Harmonisation, and the principles of the Declaration of Helsinki.</div></section><section id="sec-1-3"><h3>Trial Design</h3><div role="paragraph">This was a 56-week, phase 3, multicenter, double-blind trial of bimekizumab as compared with adalimumab; it was conducted at 77 sites (clinics, hospitals, research units, and private practices) in nine countries. The trial consisted of a screening period of 2 to 5 weeks (detailed in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org), a 16-week initial treatment period, and a 40-week maintenance treatment period (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>).</div><div role="paragraph">After the screening period, patients were randomly assigned in a 1:1:1 ratio to receive subcutaneous bimekizumab at a dose of 320 mg every 4 weeks for 56 weeks; subcutaneous bimekizumab at a dose of 320 mg every 4 weeks for 16 weeks, then every 8 weeks for weeks 16 to 56; or subcutaneous adalimumab at a dose of 80 mg at baseline, followed by 40 mg 1 week later and every 2 weeks thereafter until week 24, when these patients were switched to bimekizumab at a dose of 320 mg every 4 weeks to week 56. After completing the 56-week trial, patients could be enrolled in the BE BRIGHT open-label trial (ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03598790" target="_blank">NCT03598790</a>). Patients who were not enrolled in the open-label trial underwent a safety follow-up visit 20 weeks after their last dose of trial treatment.</div><div role="paragraph">Randomization was carried out with the use of interactive-response technology, stratified according to geographic region (North America, western Europe, central and eastern Europe, or Asia and Australia) and previous exposure to biologic agents (yes or no). To maintain double blinding, patients in all groups received dummy injections at some trial visits to account for the differences in dosing schedules among the treatment groups.</div><div role="paragraph">All trial medication was administered subcutaneously in the clinic. The investigators, other trial-site personnel, and the sponsor (with the exception of site staff responsible for the preparation and administration of trial treatments and bioanalytic sample analysis) were unaware of the trial-group assignments. Efficacy end points were assessed by the investigator, another delegated physician, or an appropriately qualified medical professional, all of whom were unaware of the trial-group assignments.</div></section><section id="sec-1-4"><h3>Efficacy End Points</h3><div role="paragraph">The primary end points were a PASI 90 response (â¥90% reduction from baseline in the PASI score) at week 16 and an IGA score of 0 or 1 (âclearâ or âalmost clear,â respectively, with at least a 2-grade improvement from baseline) at week 16. The primary end points were assessed for noninferiority (both end points were required to meet the noninferiority margin), followed by testing for superiority. The five ranked secondary efficacy end points were a PASI 100 response (complete skin clearance) at week 16, a PASI 75 response (â¥75% reduction from baseline in the PASI score) at week 4, a PASI 100 response at week 24, a PASI 90 response at week 24, and an IGA score of 0 or 1 at week 24. Exploratory end points included a Dermatology Life Quality Index (DLQI) score of 0 or 1 (on a scale from 0 to 30, with higher scores indicating lower health-related quality of life) at week 24 and a PASI 90 response, a PASI 100 response, and a DLQI score of 0 or 1 at week 56 in patients who switched from adalimumab to bimekizumab and did not have a PASI 90 response or a DLQI score of 0 or 1 at week 24.</div></section><section id="sec-1-5"><h3>Safety End Points</h3><div role="paragraph">Adverse events, serious adverse events, and adverse events leading to withdrawal were prespecified secondary end points. Adverse events with an onset on or after the first dose of trial treatment and up to 140 days after the final dose are reported. Adverse events were coded according to the <i>Medical Dictionary for Regulatory Activities</i>, version 19.0. Serious adverse events were defined as any adverse event meeting one or more of the following criteria: death, life-threatening illness, medically significant or persistent disability or incapacity, congenital anomaly or birth defect (including that occurring in a fetus), important medical event, and initial inpatient hospitalization or prolongation of hospitalization. The intensity of adverse events was recorded at each trial visit by the investigator as mild (the patient is aware of the sign or symptom, but it does not interfere with usual activities or is of no clinical consequence), moderate (the adverse event interferes with the usual activities of the patient or is of some clinical consequence), or severe (the patient is unable to work normally or to carry out usual activities, or the adverse event is of definite clinical consequence). Prespecified safety topics of interest were infections (serious, opportunistic, fungal, and tuberculosis), neutropenia, hypersensitivity, suicidal ideation and behavior, depression, major adverse cardiovascular events, changes on liver-function tests or elevated enzyme levels, cancer, and inflammatory bowel disease.</div></section><section id="sec-1-6"><h3>Statistical Analysis</h3><div role="paragraph">Sample-size calculations were based on the testing of the superiority of bimekizumab to adalimumab with respect to a PASI 90 response and an IGA score of 0 or 1 at week 16. On the basis of data from previous trials of bimekizumab and adalimumab involving patients with plaque psoriasis (BE ABLE 1, VOYAGE 1, and VOYAGE 2), the assumed incidences of a PASI 90 response were 75% with bimekizumab and 50% with adalimumab, and the assumed incidences of an IGA score of 0 or 1 were 85% and 68%, respectively.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r13 r14" id="body-ref-r14" href-manipulated="true">12-14</a></sup> Under the assumption of a sample size of 150 patients in the adalimumab group and 300 patients in the pooled bimekizumab groups, the power to detect a significant difference between bimekizumab and adalimumab at a two-sided significance level of 0.05 was more than 99% for a PASI 90 response and 97% for an IGA score of 0 or 1. These calculations were based on a two-group continuity-corrected chi-square test of equal proportions.</div><div role="paragraph">For all efficacy end points, comparisons were performed in the intention-to-treat population, which included all the patients who underwent randomization. The analyses of the primary, secondary, and exploratory end points were based on a stratified CochranâMantelâHaenszel test, in which geographic region and previous exposure to biologic agents (yes or no) were used as stratification variables. For efficacy variables, imputation of nonresponse was used to account for missing data. When the efficacy variables up to and including week 16 were examined, the two bimekizumab groups were pooled. All between-group differences that are presented for efficacy variables are adjusted risk differences from the stratified CochranâMantelâHaenszel test.</div><div role="paragraph">The primary end points were first tested for noninferiority of bimekizumab as compared with adalimumab and were then tested for superiority. For the assessment of noninferiority, a margin of â10 percentage points was used and evaluated on the basis of the confidence intervals for the CochranâMantelâHaenszel risk difference between bimekizumab and adalimumab. For the primary and ranked secondary end points, multiplicity and type I error were controlled for with the use of a fixed-sequence testing procedure with a two-sided alpha level of 0.05. Details of the statistical hierarchy are provided in Figure S2. The results for all end points not part of the statistical hierarchy are summarized with point estimates only, from which no conclusions can be drawn. Sensitivity analyses of the primary end points with multiple imputation for missing data and with additional logistic-regression models were conducted.</div><div role="paragraph">Safety to week 24 was analyzed for all the patients who received at least one dose of either trial treatment (safety set). For weeks 24 to 56, safety variables were analyzed for all the patients who had received at least one dose of bimekizumab at week 24 or beyond (bimekizumab week-24 set) because all the patients had switched from adalimumab to bimekizumab at week 24.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patient Characteristics</h3><div role="paragraph">The trial was carried out between January 26, 2018, and February 26, 2020. The delay in reporting the trial results was due to the coronavirus pandemic. A total of 614 patients were screened and 478 were enrolled; 158 patients were assigned to receive bimekizumab every 4 weeks, 161 to receive bimekizumab every 4 weeks and then every 8 weeks, and 159 to receive adalimumab every 2 weeks, followed by bimekizumab every 4 weeks starting at week 24. The demographic and clinical characteristics of the patients at baseline were similar across all treatment groups (<a href="#t1">Table 1</a>). The mean age of the patients was 44.9 years; 88.1% of the patients were White. The mean PASI score at baseline was 19.8. A total of 18 patients assigned to bimekizumab (5.6%) and 10 assigned to adalimumab (6.3%) discontinued treatment in the first 24 weeks (<a href="#f1">Figure 1</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f1.jpg"><img src="/cms/10.1056/NEJMoa2102388/asset/1fd65748-27d0-48b4-9790-f97eebe8312c/assets/images/large/nejmoa2102388_f1.jpg" height="3038" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption>Screening, Randomization, and Follow-up to Week 56.</figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2102388_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2102388_t1.jpg"><img src="/cms/10.1056/NEJMoa2102388/asset/5ab3394b-9e13-45e1-bc94-591cc72d72a8/assets/images/large/nejmoa2102388_t1.jpg" height="1611" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Bimekizumab <br>Every 4 Wk<br>(N=158)</th><th class="txxx-borders">Bimekizumab <br>Every 4 Wkâ<br>Every 8 Wk <br>(N=161)</th><th class="txxr-borders">Adalimumabâ<br>Bimekizumab <br>Every 4 Wk <br>(N=159)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age â yr</td><td class="xxxx-borders shading">45.3Â±13.2</td><td class="xxxx-borders shading">44.0Â±13.5</td><td class="xxxr-borders shading">45.5Â±14.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex â no. (%)</td><td class="xxxx-borders">102 (64.6)</td><td class="xxxx-borders">112 (69.6)</td><td class="xxxr-borders">114 (71.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">White race â no. (%)<a href="#t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">140 (88.6)</td><td class="xxxx-borders shading">140 (87.0)</td><td class="xxxr-borders shading">141 (88.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Weight â kg</td><td class="xxxx-borders">89.6Â±21.4</td><td class="xxxx-borders">93.2Â±24.4</td><td class="xxxr-borders">90.5Â±22.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Duration of psoriasis â yr</td><td class="xxxx-borders shading">20.4Â±13.2</td><td class="xxxx-borders shading">17.3Â±10.9</td><td class="xxxr-borders shading">16.2Â±11.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">PASI score<a href="#t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">20.5Â±6.9</td><td class="xxxx-borders">19.9Â±6.1</td><td class="xxxr-borders">19.0Â±5.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Affected body-surface area â %</td><td class="xxxx-borders shading">26.5Â±15.9</td><td class="xxxx-borders shading">25.2Â±12.4</td><td class="xxxr-borders shading">25.0Â±14.4</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">IGA score â no. (%)<a href="#t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">3: moderate psoriasis</td><td class="xxxx-borders shading">102 (64.6)</td><td class="xxxx-borders shading">111 (68.9)</td><td class="xxxr-borders shading">114 (71.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">4: severe psoriasis</td><td class="xxxx-borders">56 (35.4)</td><td class="xxxx-borders">50 (31.1)</td><td class="xxxr-borders">45 (28.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">DLQI score<a href="#t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders shading">11.1Â±6.5</td><td class="xxxx-borders shading">10.8Â±6.2</td><td class="xxxr-borders shading">10.5Â±7.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any previous systemic therapy â no. (%)</td><td class="xxxx-borders">112 (70.9)</td><td class="xxxx-borders">116 (72.0)</td><td class="xxxr-borders">110 (69.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Previous biologic therapy â no. (%)<a href="#t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders shading">50 (31.6)</td><td class="xxxx-borders shading">50 (31.1)</td><td class="xxxr-borders shading">53 (33.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Antiâtumor necrosis factor</td><td class="xxxx-borders">14 (8.9)</td><td class="xxxx-borders">10 (6.2)</td><td class="xxxr-borders">14 (8.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Antiâinterleukin-17</td><td class="xxxx-borders shading">33 (20.9)</td><td class="xxxx-borders shading">37 (23.0)</td><td class="xxxr-borders shading">35 (22.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Antiâinterleukin-12 and antiâinterleukin-23</td><td class="xxxx-borders">11 (7.0)</td><td class="xxxx-borders">9 (5.6)</td><td class="xxxr-borders">15 (9.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Antiâinterleukin-23</td><td class="xbxx-borders shading">3 (1.9)</td><td class="xbxx-borders shading">2 (1.2)</td><td class="xbxr-borders shading">2 (1.3)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plusâminus values are means Â±SD.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t1fn2" role="paragraph">Race was reported by the patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t1fn3" role="paragraph">Scores on the Psoriasis and Severity Index (PASI) range from 0 to 72, with higher scores indicating worse disease.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t1fn4" role="paragraph">Scores on the Investigatorâs Global Assessment (IGA) range from 0 (indicating clear skin) to 4 (indicating severe psoriasis).</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t1fn5" role="paragraph">Scores on the Dermatology Life Quality Assessment (DLQI) range from 0 to 30, with higher scores indicating lower health-related quality of life.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="t1fn6" role="paragraph">Patients who had used multiple previous biologic agents are included in the number and percentage of patients.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy Results</h3><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">Among patients receiving bimekizumab, 275 of 319 (86.2%) had a PASI 90 response (first primary end point) at week 16, as compared with 75 of 159 (47.2%) receiving adalimumab (adjusted risk difference, 39.3 percentage points; 95% confidence interval [CI], 30.9 to 47.7; P&lt;0.001 for noninferiority and superiority) (<a href="#f2">Figure 2A</a> and <a href="#t2">Table 2</a>). A total of 272 of 319 patients (85.3%) in the combined bimekizumab groups had an IGA score of 0 or 1 at week 16 (second primary end point), as compared with 91 of 159 (57.2%) in the adalimumab group (adjusted risk difference, 28.2 percentage points; 95% CI, 19.7 to 36.7; P&lt;0.001 for noninferiority and superiority) (<a href="#f2">Figure 2B</a> and <a href="#t2">Table 2</a>).</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f2.jpg"><img src="/cms/10.1056/NEJMoa2102388/asset/cb32140f-4c58-4b60-b17b-e1b2e42c2bd3/assets/images/large/nejmoa2102388_f2.jpg" height="2875" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Clinical Efficacy According to Treatment Group through 56 Weeks.</div><div class="notes"><div role="doc-footnote">Data are shown for the intention-to-treat population, which includes all the patients who underwent randomization. Percentages were calculated with the use of imputation of nonresponse. Scores on the Psoriasis Area and Severity Index (PASI) range from 0 to 72, with higher scores indicating worse disease. PASI 75, PASI 90, and PASI 100 responses indicate a reduction from baseline of at least 75%, at least 90%, and 100%, respectively, in the PASI score. Scores on the Investigatorâs Global Assessment (IGA) range from 0 (indicating clear skin) to 4 (indicating severe psoriasis). The criteria of an IGA score of 0 (clear skin) or 1 (almost clear skin) included at least a 2-grade improvement from baseline.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2102388_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2102388_t2.jpg"><img src="/cms/10.1056/NEJMoa2102388/asset/d71b835d-4625-400b-b228-9ced16fc4968/assets/images/large/nejmoa2102388_t2.jpg" height="1827" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders hanging01" data-xml-align="left">End Point</th><th class="txxx-borders">Hypothesis Test in Statistical Hierarchy</th><th class="txxx-borders">Total Bimekizumab <br>(N=319)</th><th class="txxx-borders">Adalimumab<br>(N=159)</th><th class="txxx-borders">Adjusted Risk Difference: Total Bimekizumab vs. Adalimumab <br>(95% CI)</th><th class="txxx-borders">Bimekizumab Every 4 Wk<br>(N=158)</th><th class="txxr-borders">Adjusted Risk Difference: Bimekizumab Every 4 Wk vs. Adalimumab (95% CI)</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders hanging01">&nbsp;</td><td class="xxxx-borders hanging01">&nbsp;</td><th class="xxxx-borders hanging01" colspan="2"><span>no. (%)</span></th><th class="xxxx-borders">percentage points</th><th class="xxxx-borders hanging01">no. (%)</th><th class="xxxr-borders">percentage points</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Primary end points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">PASI 90 response at wk 16<a href="#t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">H<sub>1</sub> and H<sub>3</sub></td><td class="xxxx-borders">275 (86.2)</td><td class="xxxx-borders">75 (47.2)</td><td class="xxxx-borders">39.3 <br>(30.9â47.7)<a href="#t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">NA</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">IGA score of 0 or 1 at wk 16<a href="#t2fn1" role="doc-noteref">â </a></td><td class="xxxx-borders shading">H<sub>2</sub> and H<sub>4</sub></td><td class="xxxx-borders shading">272 (85.3)</td><td class="xxxx-borders shading">91 (57.2)</td><td class="xxxx-borders shading">28.2 <br>(19.7â36.7)<a href="#t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Secondary end points</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">PASI 100 response at wk 16</td><td class="xxxx-borders shading">H<sub>5</sub></td><td class="xxxx-borders shading">194 (60.8)</td><td class="xxxx-borders shading">38 (23.9)</td><td class="xxxx-borders shading">37.0 <br>(28.6â45.3)<a href="#t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">PASI 75 response at wk 4</td><td class="xxxx-borders">H<sub>6</sub></td><td class="xxxx-borders">244 (76.5)</td><td class="xxxx-borders">50 (31.4)</td><td class="xxxx-borders">44.8 <br>(36.3â53.4)<a href="#t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">NA</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">PASI 100 response at wk 24<a href="#t2fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">H<sub>7</sub> and H<sub>10</sub></td><td class="xxxx-borders shading">213 (66.8)</td><td class="xxxx-borders shading">47 (29.6)</td><td class="xxxx-borders shading">37.1 <br>(28.5â45.7)<a href="#t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">107 (67.7)</td><td class="xxxr-borders shading">37.9 <br>(28.1â47.7)<a href="#t2fn3" role="doc-noteref">â¡</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">PASI 90 response at wk 24<a href="#t2fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">H<sub>8</sub> and H<sub>11</sub></td><td class="xxxx-borders">273 (85.6)</td><td class="xxxx-borders">82 (51.6)</td><td class="xxxx-borders">33.9 <br>(25.4â42.4)<a href="#t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">136 (86.1)</td><td class="xxxr-borders">34.3 <br>(25.2â43.5)<a href="#t2fn3" role="doc-noteref">â¡</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">IGA score of 0 or 1 at wk 24<a href="#t2fn4" role="doc-noteref">Â§</a></td><td class="xbxx-borders shading">H<sub>9</sub> and H<sub>12</sub></td><td class="xbxx-borders shading">276 (86.5)</td><td class="xbxx-borders shading">92 (57.9)</td><td class="xbxx-borders shading">28.7 <br>(20.2â37.1)<a href="#t2fn3" role="doc-noteref">â¡</a></td><td class="xbxx-borders shading">136 (86.1)</td><td class="xbxr-borders shading">28.3 <br>(19.1â37.5)<a href="#t2fn3" role="doc-noteref">â¡</a></td></tr></tbody></table></div><figcaption><div class="caption">Primary End Points and Ranked Secondary End Points.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Data are shown for the intention-to-treat population, which includes all the patients who underwent randomization. For data reported up to and including week 16, the two bimekizumab groups were pooled (the dose in the two groups was equivalent through week 16). Percentages were calculated with the use of imputation of nonresponse. PASI 75, PASI 90, and PASI 100 responses indicate a reduction from baseline of at least 75%, at least 90%, and 100%, respectively, in the PASI score. The criteria of an IGA score of 0 (clear skin) or 1 (almost clear skin) included at least a 2-grade improvement from baseline. H denotes hypothesis, and NA not applicable because tests performed on or before week 16 are based on the total bimekizumab group.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t2fn2" role="paragraph">Hypothesis tests H<sub>1</sub> and H<sub>2</sub> tested the noninferiority of bimekizumab as compared with adalimumab with respect to a PASI 90 response and an IGA score of 0 or 1, respectively, at week 16, with the use of a noninferiority margin of â10 percentage points; bimekizumab showed noninferiority as compared with adalimumab on the basis of the 95% confidence interval of the between-group difference. Hypothesis tests H<sub>3</sub> and H<sub>4</sub> tested the superiority of bimekizumab as compared with adalimumab with respect to a PASI 90 response and an IGA score of 0 or 1, respectively, at week 16.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t2fn3" role="paragraph">P&lt;0.001. P values for the comparison of treatment groups are based on the CochranâMantelâHaenszel test from the general association.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t2fn4" role="paragraph">Hypothesis tests H<sub>7</sub>, H<sub>8</sub>, and H<sub>9</sub> tested the superiority of bimekizumab as compared with adalimumab for a PASI 100 response, a PASI 90 response, and an IGA score of 0 or 1, respectively, at week 24 on the basis of the total bimekizumab group, whereas hypothesis tests H<sub>10</sub>, H<sub>11</sub>, and H<sub>12</sub> evaluated the same end points on the basis of the group receiving bimekizumab every 4 weeks.</div></div></div></figcaption></figure></div><div role="paragraph">With respect to secondary end points, 194 of 319 patients (60.8%) receiving bimekizumab had a PASI 100 response (complete skin clearance) at week 16, as compared with 38 of 159 (23.9%) receiving adalimumab (adjusted risk difference, 37.0 percentage points; 95% CI, 28.6 to 45.3; P&lt;0.001) (<a href="#f2">Figure 2C</a> and <a href="#t2">Table 2</a>). At week 4, after one dose of treatment, 244 of 319 patients (76.5%) receiving bimekizumab had a PASI 75 response, as compared with 50 of 159 (31.4%) receiving adalimumab (adjusted risk difference, 44.8 percentage points; 95% CI, 36.3 to 53.4; P&lt;0.001) (<a href="#f2">Figure 2D</a> and <a href="#t2">Table 2</a>). The percentages of patients with a PASI 100 response, a PASI 90 response, and an IGA score of 0 or 1 at week 24 were significantly higher with bimekizumab than with adalimumab (<a href="#t2">Table 2</a>).</div><div role="paragraph">A total of 134 of 158 patients (84.8%) receiving bimekizumab every 4 weeks and 133 of 161 (82.6%) receiving bimekizumab every 4 weeks and then every 8 weeks had a PASI 90 response at week 56 (<a href="#f2">Figure 2A</a>). Similar results were observed for an IGA score of 0 or 1 (<a href="#f2">Figure 2B</a>). With respect to exploratory end points (from which no definite conclusions can be made because of the lack of a plan for adjustment of confidence intervals for multiple comparisons), 114 of 158 patients (72.2%) receiving bimekizumab every 4 weeks, 113 of 161 (70.2%) receiving bimekizumab every 4 weeks and then every 8 weeks, and 106 of 159 (66.7%) who switched from adalimumab to bimekizumab at week 24 had a PASI 100 response at week 56 (<a href="#f2">Figure 2C</a>).</div><div role="paragraph">A total of 106 of 158 patients (67.1%) assigned to bimekizumab every 4 weeks, 108 of 161 (67.1%) assigned to bimekizumab every 4 weeks and then every 8 weeks, and 76 of 159 (47.8%) assigned to adalimumab had a DLQI score of 0 or 1 at week 24 (Fig. S3). Through week 56, a total of 117 of 158 patients (74.1%) assigned to bimekizumab every 4 weeks and 127 of 161 (78.9%) assigned to bimekizumab every 4 weeks and then every 8 weeks had a DLQI score of 0 or 1. Among patients switching from adalimumab to bimekizumab every 4 weeks at week 24, a total of 116 of 159 (73.0%) had a DLQI score of 0 or 1 at week 56.</div><div role="paragraph">All the patients who were initially assigned to adalimumab were switched to bimekizumab every 4 weeks at week 24. By week 24, a total of 82 of 159 patients (51.6%) who were assigned to adalimumab had a PASI 90 response. After switching to bimekizumab, 130 of 159 patients (81.8%) had a PASI 90 response at week 56. The percentage of patients who had a PASI 90 response and a DLQI score of 0 or 1 increased among patients initially assigned to adalimumab who did not have either a PASI 90 response or a DLQI score of 0 or 1 by week 24, after switching to bimekizumab. By week 56, a total of 54 of 65 patients (83%) had a PASI 90 response and 48 of 69 (70%) had a DLQI score of 0 or 1 (Fig. S4). Among patients who did not have a PASI 90 response at week 24, a total of 40 of 65 (62%) went on to have a PASI 100 response after switching to bimekizumab. The results of the sensitivity analyses of the primary end points were consistent with the results of the primary analysis (Table S1).</div></section><section id="sec-2-3"><h3>Safety Results</h3><div role="paragraph">From weeks 0 to 24, adverse events occurred in 112 of 158 patients (70.9%) assigned to bimekizumab every 4 weeks, 116 of 161 (72.0%) assigned to bimekizumab every 4 weeks and then every 8 weeks, and 111 of 159 patients (69.8%) assigned to adalimumab (<a href="#t3">Table 3</a>). <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">From weeks 0 to 24, oral candidiasis and diarrhea occurred more frequently in patients assigned to bimekizumab than in those assigned to adalimumab</span>. Serious adverse events were reported in 4 of 158 patients (2.5%) assigned to bimekizumab every 4 weeks, 1 of 161 (0.6%) assigned to bimekizumab every 4 weeks and then every 8 weeks, and 5 of 159 (3.1%) assigned to adalimumab. Discontinuations due to adverse events occurred in 3 of 158 patients (1.9%) assigned to bimekizumab every 4 weeks, 6 of 161 (3.7%) assigned to bimekizumab every 4 weeks and then every 8 weeks, and 5 of 159 (3.1%) assigned to adalimumab. One death occurred during the first 24 weeks of the trial in a 50-year-old male patient who received a diagnosis of squamous-cell carcinoma of the tongue 6 weeks after the start of adalimumab treatment, which led to death 5 months later (<a href="#t3">Table 3</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2102388_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2102388_t3.jpg"><img src="/cms/10.1056/NEJMoa2102388/asset/4fe79383-2b2d-44e0-b902-598d8736e494/assets/images/large/nejmoa2102388_t3.jpg" height="2896" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1" data-xml-valign="top"><th class="txlx-borders hanging02" data-xml-align="left">Event</th><th class="txxx-borders" colspan="3"><span>Weeks 0â24<a href="#t3fn2" role="doc-noteref">â </a></span></th><th class="txxr-borders" colspan="3"><span>Weeks 24â56<a href="#t3fn3" role="doc-noteref">â¡</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders hanging02">&nbsp;</td><th class="xxxx-borders">Bimekizumab Every 4 Wk<br>(N=158)</th><th class="xxxx-borders">Bimekizumab Every 4 Wkâ<br>Every 8 Wk<br>(N=161)</th><th class="xxxx-borders">Adalimumab<br>(N=159)</th><th class="xxxx-borders">Bimekizumab Every 4 Wk<br>(N=152)</th><th class="xxxx-borders">Bimekizumab Every 4 Wkâ<br>Every 8 Wk<br>(N=149)</th><th class="xxxr-borders">Adalimumabâ<br>Bimekizumab Every 4 Wk<br> (N=149)</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders hanging02">&nbsp;</td><th class="xxxr-borders" colspan="6"><span>number (percent)</span></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Overview</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any adverse event</td><td class="xxxx-borders">112 (70.9)</td><td class="xxxx-borders">116 (72.0)</td><td class="xxxx-borders">111 (69.8)</td><td class="xxxx-borders">101 (66.4)</td><td class="xxxx-borders">104 (69.8)</td><td class="xxxr-borders">111 (74.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders shading">4 (2.5)</td><td class="xxxx-borders shading">1 (0.6)</td><td class="xxxx-borders shading">5 (3.1)</td><td class="xxxx-borders shading">2 (1.3)</td><td class="xxxx-borders shading">8 (5.4)</td><td class="xxxr-borders shading">9 (6.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Discontinuation due to adverse event</td><td class="xxxx-borders">3 (1.9)</td><td class="xxxx-borders">6 (3.7)</td><td class="xxxx-borders">5 (3.1)</td><td class="xxxx-borders">3 (2.0)</td><td class="xxxx-borders">2 (1.3)</td><td class="xxxr-borders">5 (3.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Drug-related adverse event</td><td class="xxxx-borders shading">41 (25.9)</td><td class="xxxx-borders shading">46 (28.6)</td><td class="xxxx-borders shading">38 (23.9)</td><td class="xxxx-borders shading">40 (26.3)</td><td class="xxxx-borders shading">35 (23.5)</td><td class="xxxr-borders shading">45 (30.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Severe adverse event</td><td class="xxxx-borders">3 (1.9)</td><td class="xxxx-borders">2 (1.2)</td><td class="xxxx-borders">5 (3.1)</td><td class="xxxx-borders">5 (3.3)</td><td class="xxxx-borders">8 (5.4)</td><td class="xxxr-borders">7 (4.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.6)<a href="#t3fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Most common adverse events</b><a href="#t3fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Upper respiratory tract infection<a href="#t3fn6" role="doc-noteref">â</a></td><td class="xxxx-borders shading">48 (30.4)</td><td class="xxxx-borders shading">45 (28.0)</td><td class="xxxx-borders shading">55 (34.6)</td><td class="xxxx-borders shading">36 (23.7)</td><td class="xxxx-borders shading">36 (24.2)</td><td class="xxxr-borders shading">42 (28.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Oral candidiasis</td><td class="xxxx-borders">15 (9.5)</td><td class="xxxx-borders">19 (11.8)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">20 (13.2)</td><td class="xxxx-borders">13 (8.7)</td><td class="xxxr-borders">26 (17.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">6 (3.8)</td><td class="xxxx-borders shading">9 (5.6)</td><td class="xxxx-borders shading">13 (8.2)</td><td class="xxxx-borders shading">2 (1.3)</td><td class="xxxx-borders shading">3 (2.0)</td><td class="xxxr-borders shading">3 (2.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">8 (5.1)</td><td class="xxxx-borders">5 (3.1)</td><td class="xxxx-borders">4 (2.5)</td><td class="xxxx-borders">2 (1.3)</td><td class="xxxx-borders">3 (2.0)</td><td class="xxxr-borders">2 (1.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Adverse events of interest</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Inflammatory bowel disease</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adjudicated suicidal ideation or behavior</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Cancer<a href="#t3fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">4 (2.5)</td><td class="xxxx-borders">1 (0.6)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (1.3)</td><td class="xxxr-borders">1 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">NMSC</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (1.9)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Active tuberculosis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Latent tuberculosis</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.7)</td><td class="xxxx-borders shading">3 (2.0)</td><td class="xxxr-borders shading">1 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious hypersensitivity reaction</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adjudicated MACE</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Elevated level of liver enzymes<a href="#t3fn8" role="doc-noteref">â â </a></td><td class="xxxx-borders">3 (1.9)</td><td class="xxxx-borders">4 (2.5)</td><td class="xxxx-borders">11 (6.9)</td><td class="xxxx-borders">1 (0.7)</td><td class="xxxx-borders">2 (1.3)</td><td class="xxxr-borders">6 (4.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Serious infection<a href="#t3fn9" role="doc-noteref">â¡â¡</a></td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">1 (0.6)</td><td class="xbxx-borders shading">1 (0.6)</td><td class="xbxx-borders shading">1 (0.7)</td><td class="xbxx-borders shading">2 (1.3)</td><td class="xbxr-borders shading">4 (2.7)</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Data shown are adverse events with an onset on or after the first dose of trial treatment and up to 140 days after the final dose. MACE denotes major adverse cardiovascular event, and NMSC nonmelanoma skin cancer.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t3fn2" role="paragraph">Data for weeks 0 to 24 include all the patients who received at least one dose of bimekizumab or adalimumab (full safety set).</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t3fn3" role="paragraph">Data for weeks 24 to 56 include all the patients who had received at least one dose of bimekizumab at week 24 or beyond (bimekizumab week-24 set).</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t3fn4" role="paragraph">A 50-year-old male patient received a diagnosis of squamous-cell carcinoma of the tongue 6 weeks after the start of adalimumab treatment and died 5 months later. Mouth ulcerations were noted on screening; he had no history of tobacco use.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t3fn5" role="paragraph">Shown are adverse events that occurred in more than 5% of the patients in any treatment group from weeks 0 to 24 or from weeks 24 to 56.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="t3fn6" role="paragraph">Upper respiratory tract infections included nasopharyngitis, upper respiratory tract infection, pharyngitis, rhinitis, tonsillitis, sinusitis, acute sinusitis, chronic sinusitis, laryngitis, peritonsillar abscess, and sinobronchitis.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t3fn7" role="paragraph">From weeks 0 to 24, three cases of basal-cell carcinoma and one case of anal squamous-cell carcinoma were reported in the group receiving bimekizumab every 4 weeks and then every 8 weeks, and one case of squamous-cell carcinoma of the tongue was reported in the group receiving adalimumab. From weeks 24 to 56, one case each of colon cancer and squamous-cell carcinoma was reported in the group receiving bimekizumab every 4 weeks and then every 8 weeks, and one case of basal-cell carcinoma was reported in the group that switched from adalimumab to bimekizumab every 4 weeks at week 24.</div></div><div role="doc-footnote" data-has="label"><div class="label">â â </div><div id="t3fn8" role="paragraph">Liver-function tests included the following terms reported as adverse events: elevated levels of hepatic enzymes, aspartate aminotransferase, blood bilirubin, Î³-glutamyltransferase, alanine aminotransferase, or aminotransferases or increased liver-function test findings.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡â¡</div><div id="t3fn9" role="paragraph">From weeks 0 to 24, one case of cellulitis was reported in the group receiving bimekizumab every 4 weeks and then every 8 weeks, and one case of infected dermal cyst was reported in the group receiving adalimumab. From weeks 24 to 56, one case of subcutaneous abscess was reported in the group receiving bimekizumab every 4 weeks, one case each of appendicitis and erysipelas was reported in the group receiving bimekizumab every 4 weeks and then every 8 weeks, and two cases of cellulitis and one case each of anal abscess and helicobacter infection were reported in the group that switched from adalimumab to bimekizumab every 4 weeks at week 24.</div></div></div></figcaption></figure></div><div role="paragraph">From weeks 24 to 56, adverse events occurred in 101 of 152 patients (66.4%) assigned to bimekizumab every 4 weeks, 104 of 149 (69.8%) assigned to bimekizumab every 4 weeks and then every 8 weeks, and 111 of 149 (74.5%) assigned to adalimumab who switched to bimekizumab every 4 weeks at week 24 (<a href="#t3">Table 3</a>). Serious adverse events were reported in 2 of 152 patients (1.3%) assigned to bimekizumab every 4 weeks, 8 of 149 (5.4%) assigned to bimekizumab every 4 weeks and then every 8 weeks, and 9 of 149 (6.0%) assigned to adalimumab who switched to bimekizumab every 4 weeks at week 24 (<a href="#t3">Table 3</a>).</div><div role="paragraph">From weeks 0 to 56, there were 76 cases of oral candidiasis with bimekizumab, 36 of which were rated by investigators as moderate and 2 of which were rated as severe; none of the cases of oral candidiasis resulted in trial discontinuation. Of the other adverse events of interest, there were no instances of adjudicated major adverse cardiovascular events, adjudicated suicidal ideation or behavior, inflammatory bowel disease, serious hypersensitivity reactions, or active tuberculosis among patients treated with bimekizumab (<a href="#t3">Table 3</a>). The incidence of serious infections was similar across treatment groups.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">Bimekizumab was noninferior and superior to adalimumab with respect to a PASI 90 response and an IGA score of 0 or 1 at week 16 in patients with plaque psoriasis. By week 4, a higher percentage of patients receiving bimekizumab had a PASI 75 response than patients receiving adalimumab. Levels of skin clearance that were observed in patients who received bimekizumab were maintained through week 56, regardless of dosing regimen. More patients who received bimekizumab had a DLQI score of 0 or 1 at week 24, which was maintained through week 56.</div><div role="paragraph">Clinical responses were observed among patients who did not have a PASI 90 response or a DLQI score of 0 or 1 after 24 weeks of treatment with adalimumab and were switched to bimekizumab treatment without a period of washout of adalimumab. After 4 to 8 weeks of bimekizumab treatment, these patients had clinical responses that were similar to those of patients who had received bimekizumab from baseline.</div><div role="paragraph">Oral candidiasis and diarrhea were more common with bimekizumab than with adalimumab. Most cases of oral candidiasis were mild to moderate in intensity (97%). The incidence of oral candidiasis was similar to that reported in other phase 3 trials of bimekizumab and is presumed to be the result of the role of interleukin-17 in host defense against candida at the oral mucosa.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r10 r11" id="body-ref-r11-2" href-manipulated="true">8,10,11</a></sup></div><div role="paragraph">Limitations of this trial included the 24-week active-comparator period, which was too brief for a comparison of safety between bimekizumab and adalimumab in a lifelong disease. We used imputation of nonresponse for missing data, which has the potential to underestimate the standard error and alter estimates of differences between groups. The results of the sensitivity analyses of the primary end points that used different imputation methods were in the same direction as the results of the primary analysis. The trial drugs were administered in a clinic setting, and adherence may not be generalizable to home use by patients.</div><div role="paragraph">In this phase 3 trial involving patients with moderate-to-severe plaque psoriasis, bimekizumab resulted in higher incidences of clinical response than adalimumab over a period of 24 weeks. Longer, larger trials are required to determine the efficacy and safety of bimekizumab for the treatment of psoriasis.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on April 23, 2021, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by UCB Pharma. Dr. Warren is supported by the Manchester National Institute for Health Research Biomedical Research Centre.</div><div role="paragraph">Dr. Warren reports receiving grant support and consulting fees from AbbVie, Almirall, Bristol-Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, and UCB Pharma, consulting fees from Amgen, Arena Pharmaceuticals, Avillion, Boehringer Ingelheim, Celgene, Pfizer, Sanofi, Astellas, GlaxoSmithKline, Biogen, DiCE Molecules, Sun Pharma, and Union Therapeutics, and grant support from Medac; Dr. Blauvelt, receiving research funding and consulting fees from AbbVie, Amgen, Arcutis Biotherapeutics, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Eli Lilly, Evommune, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sun Pharma, and UCB Pharma and consulting fees from Aligos Therapeutics, Almirall, Arena Pharmaceuticals, Forte Biosciences, Galderma, Rapt Therapeutics, and Sanofi Genzyme; Dr. Bagel, receiving grant support from Arcutis Biotherapeutics, Boehringer Ingelheim, Corrona, Dermavant Sciences, Dermira, Glenmark Pharmaceuticals, Kadmon, LEO Pharma, Lycera, Menlo Therapeutics, Pfizer, Regeneron Pharmaceuticals, Taro Pharmaceutical Industries, and Ortho Dermatologics, grant support, consulting fees, and lecture fees from AbbVie, Celgene, Eli Lilly, Janssen Biotech, and Novartis, and grant support and consulting fees from Amgen, Bristol-Myers Squibb, Sun Pharmaceutical Industries, and UCB Pharma; Dr. Papp, receiving grant support, consulting fees, fees for serving on a speakers bureau, steering committee fees, and advisory board fees, all paid to his institution, and honoraria from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck (Merck Sharp &amp; Dohme), Novartis, Pfizer, Sanofi Genzyme, and Bausch Health, grant support and consulting fees, all paid to his institution, and honoraria from Akros Pharma, Coherus BioSciences, Mitsubishi Pharma, Takeda, and PRCL Research, grant support, paid to his institution, from Anacor Pharmaceuticals, GlaxoSmithKline, MedImmune, Gilead Sciences, and Moberg Pharma, grant support and consulting fees, all paid to his institution, from Arcutis Biotherapeutics, Baxalta, Can-Fite BioPharma, Dermira, Genentech, Meiji Seika Pharma, Roche, Evelo Biosciences, Galapagos, Avillion, and DiCE Molecules, grant support, consulting fees, fees for serving on a speakers bureau, and advisory board fees from Astellas, grant support, consulting fees, steering committee fees, and advisory board fees, all paid to his institution, and honoraria from Boehringer Ingelheim and Regeneron Pharmaceuticals, grant support, consulting fees, and advisory board fees, all paid to his institution, from Bristol-Myers Squibb, Dow Pharma, and Dermavant Sciences, grant support, consulting fees, fees for serving on a speakers bureau, and advisory board fees, all paid to his institution, and honoraria from Galderma, grant support, consulting fees, fees for serving on a speakers bureau, and advisory board fees, all paid to his institution, and honoraria from Kyowa Hakko Kirin, grant support, consulting fees, and fees for serving on a speakers bureau, all paid to his institution, from LEO Pharma and Incyte, grant support, consulting fees, and steering committee fees, all paid to his institution, and honoraria from Merck Serono, grant support, consulting fees, and advisory board fees, all paid to his institution, and honoraria from UCB Pharma, and grant support and advisory board fees, all paid to his institution, from Sun Pharma; Dr. Yamauchi, receiving lecture fees, consulting fees, and investigator fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, and UCB Pharma; Dr. Armstrong, receiving grant support, advisory fees, and lecture fees from AbbVie and Regeneron Pharmaceuticals, grant support and advisory fees from Bristol-Myers Squibb, Dermavant Sciences, Dermira, Eli Lilly, LEO Pharma, Novartis, and UCB Pharma, advisory fees from Janssen, Modernizing Medicine, Ortho Dermatologics, Sanofi Genzyme, Sun Pharma, and Pfizer, grant support from Kyowa Kirin and Galderma, and fees for serving on a data and safety monitoring board from Boehringer Ingelheim and Parexel; Dr. Langley, receiving grant support, advisory board fees, investigator fees, and lecture fees from AbbVie, Amgen, Centocor, Eli Lilly, Janssen, LEO Pharma, Novartis, UCB Pharma, and Celgene and grant support, advisory board fees, and investigator fees from Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Merck; Ms. Vanvoorden, Drs. De Cuyper and Cioffi, Mr. Peterson, and Dr. Cross, being employed by and owning shares in UCB Pharma; and Dr. Reich, receiving grant support, consulting fees, and lecture fees from AbbVie, Almirall, Biogen Idec, Celgene, Eli Lilly, Janssen-Cilag, LEO Pharma, Medac, Merck Sharp &amp; Dohme, Novartis, and Sanofi, grant support and consulting fees from Affibody, Boehringer Ingelheim, Covagen, Forward Pharma, Galderma, Kyowa Kirin, Ocean Pharma, Pfizer, Sun Pharma, Takeda, UCB Pharma, and Bristol-Myers Squibb, consulting fees from Amgen, GlaxoSmithKline, Samsung Bioepis, and XenoPort, lecture fees from Valeant Pharmaceuticals and Sandoz, and grant support from Fresenius Medical Care, Galapagos, Miltenyi Biotec, and XBiotech. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients and their caregivers in addition to all the investigators and their teams who contributed to this trial; Susanne Wiegratz, M.Sc., of UCB Pharma (Monheim, Germany) for publication coordination; Natalie Nunez Gomez, M.D., of UCB Pharma (Brussels) for critical review; and Ruth Moulson, M.P.H., of Costello Medical (London) for medical writing and editorial assistance with an earlier version of the manuscript, in accordance with Good Publication Practice 3 guidelines (<a href="http://www.ismpp.org/gpp3" target="_blank">http://www.ismpp.org/gpp3</a>).</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2102388_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2102388/suppl_file/nejmoa2102388_research-summary.pdf" download="nejmoa2102388_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2102388_research-summary.pdf" data-doi="10.1056/NEJMoa2102388">Download</a></li><li>1.95 MB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2102388_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2102388/suppl_file/nejmoa2102388_protocol.pdf" download="nejmoa2102388_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2102388_protocol.pdf" data-doi="10.1056/NEJMoa2102388">Download</a></li><li>8.70 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2102388_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2102388/suppl_file/nejmoa2102388_appendix.pdf" download="nejmoa2102388_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2102388_appendix.pdf" data-doi="10.1056/NEJMoa2102388">Download</a></li><li>511.02 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2102388_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2102388/suppl_file/nejmoa2102388_disclosures.pdf" download="nejmoa2102388_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2102388_disclosures.pdf" data-doi="10.1056/NEJMoa2102388">Download</a></li><li>354.50 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2102388_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2102388/suppl_file/nejmoa2102388_data-sharing.pdf" download="nejmoa2102388_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2102388_data-sharing.pdf" data-doi="10.1056/NEJMoa2102388">Download</a></li><li>69.77 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <em>Cochrane Database Syst Rev</em> 2020;1:CD011535-CD011535.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31917873/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000510398500041" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systemic+pharmacological+treatments+for+chronic+plaque+psoriasis%3A+a+network+meta-analysis.&amp;publication_year=2020&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD011535-CD011535&amp;pmid=31917873" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. <em>J Immunol</em> 2018;201:1605-1613.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1800013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30181299/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000443585800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Discovery+of+the+IL-23%2FIL-17+signaling+pathway+and+the+treatment+of+psoriasis.&amp;publication_year=2018&amp;journal=J+Immunol&amp;pages=1605-1613&amp;doi=10.4049%2Fjimmunol.1800013&amp;pmid=30181299" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Brembilla NC, Senra L, Boehncke W-H. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. <em>Front Immunol</em> 2018;9:1682-1682.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3389/fimmu.2018.01682" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30127781/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000440582100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+IL-17+family+of+cytokines+in+psoriasis%3A+IL-17A+and+beyond.&amp;publication_year=2018&amp;journal=Front+Immunol&amp;pages=1682-1682&amp;doi=10.3389%2Ffimmu.2018.01682&amp;pmid=30127781" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Prignano F, Choi J, Pieper B, Iversen L. Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars. <em>Expert Opin Biol Ther</em> 2021;21:75-80.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/14712598.2020.1812576" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32886008/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000566964500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anti-tumor+necrosis+factor+agents+in+psoriasis%3A+addressing+key+challenges+using+biosimilars.&amp;publication_year=2021&amp;journal=Expert+Opin+Biol+Ther&amp;pages=75-80&amp;doi=10.1080%2F14712598.2020.1812576&amp;pmid=32886008" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. <em>Ann Rheum Dis</em> 2018;77:523-532.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/annrheumdis-2017-212127" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29275332/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000429731800014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dual+IL-17A+and+IL-17F+neutralisation+by+bimekizumab+in+psoriatic+arthritis%3A+evidence+from+preclinical+experiments+and+a+randomised+placebo-controlled+clinical+trial+that+IL-17F+contributes+to+human+chronic+tissue+inflammation.&amp;publication_year=2018&amp;journal=Ann+Rheum+Dis&amp;pages=523-532&amp;doi=10.1136%2Fannrheumdis-2017-212127&amp;pmid=29275332" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Yost J, Gudjonsson JE. The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities. <em>F1000 Med Rep</em> 2009;1:30-30.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3410/M1-30" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20948750/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+role+of+TNF+inhibitors+in+psoriasis+therapy%3A+new+implications+for+associated+comorbidities.&amp;publication_year=2009&amp;journal=F1000+Med+Rep&amp;pages=30-30&amp;doi=10.3410%2FM1-30&amp;pmid=20948750" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Warren RB, See K, Burge R, et al. Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network meta-analyses. <em>Dermatol Ther (Heidelb)</em> 2020;10:73-86.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s13555-019-00337-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31686337/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000493933000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rapid+response+of+biologic+treatments+of+moderate-to-severe+plaque+psoriasis%3A+a+comprehensive+investigation+using+Bayesian+and+frequentist+network+meta-analyses.&amp;publication_year=2020&amp;journal=Dermatol+Ther+%28Heidelb%29&amp;pages=73-86&amp;doi=10.1007%2Fs13555-019-00337-y&amp;pmid=31686337" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <em>Lancet</em> 2021;397:487-498.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)00125-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33549193/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000616661900024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bimekizumab+versus+ustekinumab+for+the+treatment+of+moderate+to+severe+plaque+psoriasis+%28BE+VIVID%29%3A+efficacy+and+safety+from+a+52-week%2C+multicentre%2C+double-blind%2C+active+comparator+and+placebo+controlled+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=487-498&amp;doi=10.1016%2FS0140-6736%2821%2900125-2&amp;pmid=33549193" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] isoforms, including interleukin-17F/17F. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the interleukin-17A inhibitor secukinumab. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] defense against candida at the oral mucosa. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. <em>Br J Clin Pharmacol</em> 2017;83:991-1001.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bcp.13185" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27859546/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000401234300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-in-human+randomized+study+of+bimekizumab%2C+a+humanized+monoclonal+antibody+and+selective+dual+inhibitor+of+IL-17A+and+IL-17F%2C+in+mild+psoriasis.&amp;publication_year=2017&amp;journal=Br+J+Clin+Pharmacol&amp;pages=991-1001&amp;doi=10.1111%2Fbcp.13185&amp;pmid=27859546" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. <em>Lancet</em> 2021;397:475-486.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)00126-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33549192/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000616661900023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bimekizumab+efficacy+and+safety+in+moderate+to+severe+plaque+psoriasis+%28BE+READY%29%3A+a+multicentre%2C+double-blind%2C+placebo-controlled%2C+randomised+withdrawal+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=475-486&amp;doi=10.1016%2FS0140-6736%2821%2900126-4&amp;pmid=33549192" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the interleukin-17A inhibitor secukinumab. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] defense against candida at the oral mucosa. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. <em>N Engl J Med</em> 2021;384:142-152.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_12_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2102388&amp;key=10.1056%2FNEJMoa2102383&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000643851000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bimekizumab+versus+secukinumab+in+plaque+psoriasis.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=142-152&amp;doi=10.1056%2FNEJMoa2102383" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the interleukin-17A inhibitor secukinumab. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] defense against candida at the oral mucosa. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <em>J Am Acad Dermatol</em> 2018;79(2):277.e10-286.e10.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2018.03.037" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29609013/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000438603100023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dual+neutralization+of+both+interleukin+17A+and+interleukin+17F+with+bimekizumab+in+patients+with+psoriasis%3A+results+from+BE+ABLE+1%2C+a+12-week+randomized%2C+double-blinded%2C+placebo-controlled+phase+2b+trial.&amp;publication_year=2018&amp;journal=J+Am+Acad+Dermatol&amp;pages=277.e10-286.e10&amp;doi=10.1016%2Fj.jaad.2018.03.037&amp;pmid=29609013" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <em>J Am Acad Dermatol</em> 2017;76:405-417.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2016.11.041" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28057360/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000402797000057" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+guselkumab%2C+an+anti-interleukin-23+monoclonal+antibody%2C+compared+with+adalimumab+for+the+continuous+treatment+of+patients+with+moderate+to+severe+psoriasis%3A+results+from+the+phase+III%2C+double-blinded%2C+placebo-+and+active+comparator-controlled+VOYAGE+1+trial.&amp;publication_year=2017&amp;journal=J+Am+Acad+Dermatol&amp;pages=405-417&amp;doi=10.1016%2Fj.jaad.2016.11.041&amp;pmid=28057360" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. <em>J Am Acad Dermatol</em> 2017;76:418-431.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2016.11.042" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28057361/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000402797000058" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+guselkumab%2C+an+anti-interleukin-23+monoclonal+antibody%2C+compared+with+adalimumab+for+the+treatment+of+patients+with+moderate+to+severe+psoriasis+with+randomized+withdrawal+and+retreatment%3A+results+from+the+phase+III%2C+double-blind%2C+placebo-+and+active+comparator-controlled+VOYAGE+2+trial.&amp;publication_year=2017&amp;journal=J+Am+Acad+Dermatol&amp;pages=418-431&amp;doi=10.1016%2Fj.jaad.2016.11.042&amp;pmid=28057361" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/385/2"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">385</span></span> â¢ <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">2</span></span> â¢ <span property="datePublished">July 8, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">130</span>-<span property="pageEnd">141</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright Â© 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: April 23, 2021</div><div><b class="core-label">Published in issue</b>: July 8, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/psoriasis" alt="View article keyword Psoriasis" data-interactiontype="article_recirculation_click">Psoriasis</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/rheumatology-general" alt="View article keyword Rheumatology General" data-interactiontype="article_recirculation_click">Rheumatology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Richard B.</span> <span property="familyName">Warren</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andrew</span> <span property="familyName">Blauvelt</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jerry</span> <span property="familyName">Bagel</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kim A.</span> <span property="familyName">Papp</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9557-3642" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9557-3642</a></span>, <span property="author" typeof="Person"><span property="givenName">Paul</span> <span property="familyName">Yamauchi</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">April</span> <span property="familyName">Armstrong</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Richard G.</span> <span property="familyName">Langley</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Veerle</span> <span property="familyName">Vanvoorden</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Dirk</span> <span property="familyName">De Cuyper</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christopher</span> <span property="familyName">Cioffi</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Luke</span> <span property="familyName">Peterson</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nancy</span> <span property="familyName">Cross</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Kristian</span> <span property="familyName">Reich</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) â both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) â both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center HamburgâEppendorf, Hamburg, Germany (K.R.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Warren at the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester M13 9PL, United Kingdom, or at <a href="mailto:richard.warren@manchester.ac.uk">richard.warren@manchester.ac.uk</a>.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">157</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2102388" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="ce537906-588c-2ad7-b657-31d9ceb658a5"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104545708" style="display:inline-block;">
                <img alt="Article has an altmetric score of 267" src="https://badges.altmetric.com/?size=320&amp;score=267&amp;types=mabvtwfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104545708">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_ce537906-588c-2ad7-b657-31d9ceb658a5" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104545708&amp;tab=news">
          Picked up by <b>34</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104545708&amp;tab=blogs">
          Blogged by <b>4</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104545708&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104545708&amp;tab=twitter">
          Posted by <b>20</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104545708&amp;tab=patents">
          Referenced in <b>2</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104545708&amp;tab=facebook">
          On <b>1</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104545708&amp;tab=wikipedia">
          Referenced in <b>3</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=104545708&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>288</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d68ba925aef18e-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2102388"> <input type="hidden" name="downloadFileName" value="csp_385_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2102388%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-2%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="157" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jia-Xin Zhang, </li><li class="list-inline-item cited-by__entry__author">Wen-Wei Li, </li><li class="list-inline-item cited-by__entry__author">Long-Zhuan Huang, </li><li class="list-inline-item cited-by__entry__author">Sha Lai, </li><li class="list-inline-item cited-by__entry__author">Zhi-Kun Qiu, </li></ul><span class="cited-by__entry__title">Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis, </span><span class="cited-by__entry__series-title">Frontiers in Immunology, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fimmu.2025.1594998" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fimmu.2025.1594998</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fimmu.2025.1594998" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nikki Zangenah, </li><li class="list-inline-item cited-by__entry__author">Maria Vazquez-Machado, </li><li class="list-inline-item cited-by__entry__author">Nicole Loranger, </li><li class="list-inline-item cited-by__entry__author">Soha Elshaboury, </li><li class="list-inline-item cited-by__entry__author">Kimberly Hashemi, </li><li class="list-inline-item cited-by__entry__author">Avery H. LaChance, </li></ul><span class="cited-by__entry__title">Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis, </span><span class="cited-by__entry__series-title">JAAD International, </span><span class="cited-by__entry__volume"><strong>20</strong>, </span><span class="cited-by__entry__page-range">(54-55), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jdin.2025.02.001" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jdin.2025.02.001</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jdin.2025.02.001" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Maria Esposito, </li><li class="list-inline-item cited-by__entry__author">Paolo Gisondi, </li><li class="list-inline-item cited-by__entry__author">Chiara Assorgi, </li><li class="list-inline-item cited-by__entry__author">Francesco Bellinato, </li><li class="list-inline-item cited-by__entry__author">Pina Brianti, </li><li class="list-inline-item cited-by__entry__author">Martina Burlando, </li><li class="list-inline-item cited-by__entry__author">Giovanna Brunasso, </li><li class="list-inline-item cited-by__entry__author">Stefano Caccavale, </li><li class="list-inline-item cited-by__entry__author">Giacomo Caldarola, </li><li class="list-inline-item cited-by__entry__author">Elena Campione, </li><li class="list-inline-item cited-by__entry__author">Piergiacomo Calzavara Pinton, </li><li class="list-inline-item cited-by__entry__author">Anna Campanati, </li><li class="list-inline-item cited-by__entry__author">Carlo Giovanni Carrera, </li><li class="list-inline-item cited-by__entry__author">Andrea Carugno, </li><li class="list-inline-item cited-by__entry__author">Emanuele Cozzani, </li><li class="list-inline-item cited-by__entry__author">Antonio Costanzo, </li><li class="list-inline-item cited-by__entry__author">Francesco Cusano, </li><li class="list-inline-item cited-by__entry__author">Paolo Dapavo, </li><li class="list-inline-item cited-by__entry__author">Annunziata Dattola, </li><li class="list-inline-item cited-by__entry__author">Clara De Simone, </li><li class="list-inline-item cited-by__entry__author">Roberta Di Caprio, </li><li class="list-inline-item cited-by__entry__author">Federico Diotallevi, </li><li class="list-inline-item cited-by__entry__author">Maria Concetta Fargnoli, </li><li class="list-inline-item cited-by__entry__author">Francesca Gaiani, </li><li class="list-inline-item cited-by__entry__author">Alessandro Giunta, </li><li class="list-inline-item cited-by__entry__author">Piergiorgio Malagoli, </li><li class="list-inline-item cited-by__entry__author">Angelo Valerio Marzano, </li><li class="list-inline-item cited-by__entry__author">Matteo Megna, </li><li class="list-inline-item cited-by__entry__author">Santo Raffaele Mercuri, </li><li class="list-inline-item cited-by__entry__author">Edoardo Mortato, </li><li class="list-inline-item cited-by__entry__author">Alessandra Narcisi, </li><li class="list-inline-item cited-by__entry__author">Diego Orsini, </li><li class="list-inline-item cited-by__entry__author">Luca Potestio, </li><li class="list-inline-item cited-by__entry__author">Pietro Quaglino, </li><li class="list-inline-item cited-by__entry__author">Antonio Giovanni Richetta, </li><li class="list-inline-item cited-by__entry__author">Francesca Romano, </li><li class="list-inline-item cited-by__entry__author">Paolo Sena, </li><li class="list-inline-item cited-by__entry__author">Emanuele Vagnozzi, </li><li class="list-inline-item cited-by__entry__author">Marina Venturini, </li><li class="list-inline-item cited-by__entry__author">Francesco Loconsole, </li><li class="list-inline-item cited-by__entry__author">Anna Balato, </li></ul><span class="cited-by__entry__title">Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life ObservationâIL PSO (Italian Landscape Psoriasis), </span><span class="cited-by__entry__series-title">Clinical Drug Investigation, </span><span class="cited-by__entry__volume"><strong>45</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(309-315), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s40261-025-01440-z" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s40261-025-01440-z</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s40261-025-01440-z" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mark G. Lebwohl, </li><li class="list-inline-item cited-by__entry__author">AndrÃ© Carvalho, </li><li class="list-inline-item cited-by__entry__author">Akihiko Asahina, </li><li class="list-inline-item cited-by__entry__author">Jianzhong Zhang, </li><li class="list-inline-item cited-by__entry__author">Mir Sohail Fazeli, </li><li class="list-inline-item cited-by__entry__author">Ellen Kasireddy, </li><li class="list-inline-item cited-by__entry__author">Paul Serafini, </li><li class="list-inline-item cited-by__entry__author">Thomas Ferro, </li><li class="list-inline-item cited-by__entry__author">Ranga Gogineni, </li><li class="list-inline-item cited-by__entry__author">Diamant ThaÃ§i, </li></ul><span class="cited-by__entry__title">Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis, </span><span class="cited-by__entry__series-title">Dermatology and Therapy, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">7, </span><span class="cited-by__entry__page-range">(1633-1656), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s13555-025-01423-0" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s13555-025-01423-0</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s13555-025-01423-0" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Carlota Abbad-Jaime De AragÃ³n, </li><li class="list-inline-item cited-by__entry__author">Emilio Berna-Rico, </li><li class="list-inline-item cited-by__entry__author">Pedro JaÃ©n, </li><li class="list-inline-item cited-by__entry__author">Andrew Blauvelt, </li><li class="list-inline-item cited-by__entry__author">Ãlvaro GonzÃ¡lez-Cantero, </li></ul><span class="cited-by__entry__title">Bimekizumab as-needed dosing in patients with psoriasis: a case series, </span><span class="cited-by__entry__series-title">Journal of Dermatological Treatment, </span><span class="cited-by__entry__volume"><strong>36</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/09546634.2025.2492197" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/09546634.2025.2492197</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/09546634.2025.2492197" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kosuke Noma, </li><li class="list-inline-item cited-by__entry__author">Takaki Asano, </li><li class="list-inline-item cited-by__entry__author">Maki Taniguchi, </li><li class="list-inline-item cited-by__entry__author">Kosuke Ashihara, </li><li class="list-inline-item cited-by__entry__author">Satoshi Okada, </li></ul><span class="cited-by__entry__title">Anti-cytokine autoantibodies in human susceptibility to infectious diseases: insights from Inborn errors of immunity, </span><span class="cited-by__entry__series-title">Immunological Medicine, </span><span class="cited-by__entry__volume"><strong>48</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(124-140), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/25785826.2025.2488553" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/25785826.2025.2488553</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/25785826.2025.2488553" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Zhongyuan Tang, </li><li class="list-inline-item cited-by__entry__author">Lijian Jin, </li><li class="list-inline-item cited-by__entry__author">Yanqi Yang, </li></ul><span class="cited-by__entry__title">The dual role of IL-17 in periodontitis regulating immunity and bone homeostasis, </span><span class="cited-by__entry__series-title">Frontiers in Immunology, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fimmu.2025.1578635" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fimmu.2025.1578635</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fimmu.2025.1578635" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Meitong Ou, </li><li class="list-inline-item cited-by__entry__author">Jiahui Cao, </li><li class="list-inline-item cited-by__entry__author">Ran Luo, </li><li class="list-inline-item cited-by__entry__author">Baisong Zhu, </li><li class="list-inline-item cited-by__entry__author">Rourou Miao, </li><li class="list-inline-item cited-by__entry__author">Liu Yu, </li><li class="list-inline-item cited-by__entry__author">Xinyi Wang, </li><li class="list-inline-item cited-by__entry__author">Wen Li, </li><li class="list-inline-item cited-by__entry__author">Yiqiu Fu, </li><li class="list-inline-item cited-by__entry__author">Jinxie Zhang, </li><li class="list-inline-item cited-by__entry__author">Fan Zhang, </li><li class="list-inline-item cited-by__entry__author">Qiangsong Wang, </li><li class="list-inline-item cited-by__entry__author">Lin Mei, </li></ul><span class="cited-by__entry__title">Drug-loaded microneedle patches containing regulatory T cell-derived exosomes for psoriasis treatment, </span><span class="cited-by__entry__series-title">Acta Biomaterialia, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.actbio.2025.04.015" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.actbio.2025.04.015</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.actbio.2025.04.015" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Michael Sebastian, </li><li class="list-inline-item cited-by__entry__author">Jerry Bagel, </li><li class="list-inline-item cited-by__entry__author">Bengt Hoepken, </li><li class="list-inline-item cited-by__entry__author">Bertram Knapp, </li><li class="list-inline-item cited-by__entry__author">Ceyhun Bicer, </li><li class="list-inline-item cited-by__entry__author">Merran MacPherson, </li><li class="list-inline-item cited-by__entry__author">Richard G. Langley, </li></ul><span class="cited-by__entry__title">Single-Injection Options for Administering a 320&nbsp;mg Dose of Bimekizumab: 2&nbsp;mL Safety Syringe and Auto-injector, </span><span class="cited-by__entry__series-title">Dermatology and Therapy, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(1113-1134), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s13555-025-01366-6" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s13555-025-01366-6</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s13555-025-01366-6" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yufei Xie, </li><li class="list-inline-item cited-by__entry__author">Maosheng Chai, </li><li class="list-inline-item cited-by__entry__author">Yixiao Xing, </li><li class="list-inline-item cited-by__entry__author">Peiru Zhou, </li><li class="list-inline-item cited-by__entry__author">Pan Wei, </li><li class="list-inline-item cited-by__entry__author">Hong Hua, </li></ul><span class="cited-by__entry__title">miRNA let-7f-5p-encapsulated labial gland MSC-derived EVs ameliorate experimental SjÃ¶grenâs syndrome by suppressing Th17 cells via targeting RORC/IL-17A signaling axis, </span><span class="cited-by__entry__series-title">Journal of Nanobiotechnology, </span><span class="cited-by__entry__volume"><strong>23</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s12951-025-03308-y" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s12951-025-03308-y</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s12951-025-03308-y" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2102388%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-2%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2102388" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2102388" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2102388.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f0.jpg"><img src="/cms/10.1056/NEJMoa2102388/asset/d986ea30-c4c8-4e55-84b1-561a5256a379/assets/images/large/nejmoa2102388_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f1.jpg"><img src="/cms/10.1056/NEJMoa2102388/asset/1fd65748-27d0-48b4-9790-f97eebe8312c/assets/images/large/nejmoa2102388_f1.jpg" height="3038" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption>Screening, Randomization, and Follow-up to Week 56.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f2.jpg"><img src="/cms/10.1056/NEJMoa2102388/asset/cb32140f-4c58-4b60-b17b-e1b2e42c2bd3/assets/images/large/nejmoa2102388_f2.jpg" height="2875" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Clinical Efficacy According to Treatment Group through 56 Weeks.</div><div class="notes"><div role="doc-footnote">Data are shown for the intention-to-treat population, which includes all the patients who underwent randomization. Percentages were calculated with the use of imputation of nonresponse. Scores on the Psoriasis Area and Severity Index (PASI) range from 0 to 72, with higher scores indicating worse disease. PASI 75, PASI 90, and PASI 100 responses indicate a reduction from baseline of at least 75%, at least 90%, and 100%, respectively, in the PASI score. Scores on the Investigatorâs Global Assessment (IGA) range from 0 (indicating clear skin) to 4 (indicating severe psoriasis). The criteria of an IGA score of 0 (clear skin) or 1 (almost clear skin) included at least a 2-grade improvement from baseline.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2102388_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2102388/asset/5ab3394b-9e13-45e1-bc94-591cc72d72a8/assets/images/large/nejmoa2102388_t1.jpg" height="1611" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Bimekizumab <br>Every 4 Wk<br>(N=158)</th><th class="txxx-borders">Bimekizumab <br>Every 4 Wkâ<br>Every 8 Wk <br>(N=161)</th><th class="txxr-borders">Adalimumabâ<br>Bimekizumab <br>Every 4 Wk <br>(N=159)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age â yr</td><td class="xxxx-borders shading">45.3Â±13.2</td><td class="xxxx-borders shading">44.0Â±13.5</td><td class="xxxr-borders shading">45.5Â±14.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex â no. (%)</td><td class="xxxx-borders">102 (64.6)</td><td class="xxxx-borders">112 (69.6)</td><td class="xxxr-borders">114 (71.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">White race â no. (%)<a href="#core-t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">140 (88.6)</td><td class="xxxx-borders shading">140 (87.0)</td><td class="xxxr-borders shading">141 (88.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Weight â kg</td><td class="xxxx-borders">89.6Â±21.4</td><td class="xxxx-borders">93.2Â±24.4</td><td class="xxxr-borders">90.5Â±22.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Duration of psoriasis â yr</td><td class="xxxx-borders shading">20.4Â±13.2</td><td class="xxxx-borders shading">17.3Â±10.9</td><td class="xxxr-borders shading">16.2Â±11.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">PASI score<a href="#core-t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">20.5Â±6.9</td><td class="xxxx-borders">19.9Â±6.1</td><td class="xxxr-borders">19.0Â±5.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Affected body-surface area â %</td><td class="xxxx-borders shading">26.5Â±15.9</td><td class="xxxx-borders shading">25.2Â±12.4</td><td class="xxxr-borders shading">25.0Â±14.4</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">IGA score â no. (%)<a href="#core-t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">3: moderate psoriasis</td><td class="xxxx-borders shading">102 (64.6)</td><td class="xxxx-borders shading">111 (68.9)</td><td class="xxxr-borders shading">114 (71.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">4: severe psoriasis</td><td class="xxxx-borders">56 (35.4)</td><td class="xxxx-borders">50 (31.1)</td><td class="xxxr-borders">45 (28.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">DLQI score<a href="#core-t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders shading">11.1Â±6.5</td><td class="xxxx-borders shading">10.8Â±6.2</td><td class="xxxr-borders shading">10.5Â±7.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any previous systemic therapy â no. (%)</td><td class="xxxx-borders">112 (70.9)</td><td class="xxxx-borders">116 (72.0)</td><td class="xxxr-borders">110 (69.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Previous biologic therapy â no. (%)<a href="#core-t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders shading">50 (31.6)</td><td class="xxxx-borders shading">50 (31.1)</td><td class="xxxr-borders shading">53 (33.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Antiâtumor necrosis factor</td><td class="xxxx-borders">14 (8.9)</td><td class="xxxx-borders">10 (6.2)</td><td class="xxxr-borders">14 (8.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Antiâinterleukin-17</td><td class="xxxx-borders shading">33 (20.9)</td><td class="xxxx-borders shading">37 (23.0)</td><td class="xxxr-borders shading">35 (22.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Antiâinterleukin-12 and antiâinterleukin-23</td><td class="xxxx-borders">11 (7.0)</td><td class="xxxx-borders">9 (5.6)</td><td class="xxxr-borders">15 (9.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Antiâinterleukin-23</td><td class="xbxx-borders shading">3 (1.9)</td><td class="xbxx-borders shading">2 (1.2)</td><td class="xbxr-borders shading">2 (1.3)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plusâminus values are means Â±SD.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race was reported by the patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Scores on the Psoriasis and Severity Index (PASI) range from 0 to 72, with higher scores indicating worse disease.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Scores on the Investigatorâs Global Assessment (IGA) range from 0 (indicating clear skin) to 4 (indicating severe psoriasis).</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Scores on the Dermatology Life Quality Assessment (DLQI) range from 0 to 30, with higher scores indicating lower health-related quality of life.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Patients who had used multiple previous biologic agents are included in the number and percentage of patients.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2102388_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2102388_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2102388/asset/d71b835d-4625-400b-b228-9ced16fc4968/assets/images/large/nejmoa2102388_t2.jpg" height="1827" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders hanging01" data-xml-align="left">End Point</th><th class="txxx-borders">Hypothesis Test in Statistical Hierarchy</th><th class="txxx-borders">Total Bimekizumab <br>(N=319)</th><th class="txxx-borders">Adalimumab<br>(N=159)</th><th class="txxx-borders">Adjusted Risk Difference: Total Bimekizumab vs. Adalimumab <br>(95% CI)</th><th class="txxx-borders">Bimekizumab Every 4 Wk<br>(N=158)</th><th class="txxr-borders">Adjusted Risk Difference: Bimekizumab Every 4 Wk vs. Adalimumab (95% CI)</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders hanging01">&nbsp;</td><td class="xxxx-borders hanging01">&nbsp;</td><th class="xxxx-borders hanging01" colspan="2"><span>no. (%)</span></th><th class="xxxx-borders">percentage points</th><th class="xxxx-borders hanging01">no. (%)</th><th class="xxxr-borders">percentage points</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Primary end points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">PASI 90 response at wk 16<a href="#core-t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">H<sub>1</sub> and H<sub>3</sub></td><td class="xxxx-borders">275 (86.2)</td><td class="xxxx-borders">75 (47.2)</td><td class="xxxx-borders">39.3 <br>(30.9â47.7)<a href="#core-t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">NA</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">IGA score of 0 or 1 at wk 16<a href="#core-t2fn1" role="doc-noteref">â </a></td><td class="xxxx-borders shading">H<sub>2</sub> and H<sub>4</sub></td><td class="xxxx-borders shading">272 (85.3)</td><td class="xxxx-borders shading">91 (57.2)</td><td class="xxxx-borders shading">28.2 <br>(19.7â36.7)<a href="#core-t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Secondary end points</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">PASI 100 response at wk 16</td><td class="xxxx-borders shading">H<sub>5</sub></td><td class="xxxx-borders shading">194 (60.8)</td><td class="xxxx-borders shading">38 (23.9)</td><td class="xxxx-borders shading">37.0 <br>(28.6â45.3)<a href="#core-t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">PASI 75 response at wk 4</td><td class="xxxx-borders">H<sub>6</sub></td><td class="xxxx-borders">244 (76.5)</td><td class="xxxx-borders">50 (31.4)</td><td class="xxxx-borders">44.8 <br>(36.3â53.4)<a href="#core-t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">NA</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">PASI 100 response at wk 24<a href="#core-t2fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">H<sub>7</sub> and H<sub>10</sub></td><td class="xxxx-borders shading">213 (66.8)</td><td class="xxxx-borders shading">47 (29.6)</td><td class="xxxx-borders shading">37.1 <br>(28.5â45.7)<a href="#core-t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">107 (67.7)</td><td class="xxxr-borders shading">37.9 <br>(28.1â47.7)<a href="#core-t2fn3" role="doc-noteref">â¡</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">PASI 90 response at wk 24<a href="#core-t2fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">H<sub>8</sub> and H<sub>11</sub></td><td class="xxxx-borders">273 (85.6)</td><td class="xxxx-borders">82 (51.6)</td><td class="xxxx-borders">33.9 <br>(25.4â42.4)<a href="#core-t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">136 (86.1)</td><td class="xxxr-borders">34.3 <br>(25.2â43.5)<a href="#core-t2fn3" role="doc-noteref">â¡</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">IGA score of 0 or 1 at wk 24<a href="#core-t2fn4" role="doc-noteref">Â§</a></td><td class="xbxx-borders shading">H<sub>9</sub> and H<sub>12</sub></td><td class="xbxx-borders shading">276 (86.5)</td><td class="xbxx-borders shading">92 (57.9)</td><td class="xbxx-borders shading">28.7 <br>(20.2â37.1)<a href="#core-t2fn3" role="doc-noteref">â¡</a></td><td class="xbxx-borders shading">136 (86.1)</td><td class="xbxr-borders shading">28.3 <br>(19.1â37.5)<a href="#core-t2fn3" role="doc-noteref">â¡</a></td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Data are shown for the intention-to-treat population, which includes all the patients who underwent randomization. For data reported up to and including week 16, the two bimekizumab groups were pooled (the dose in the two groups was equivalent through week 16). Percentages were calculated with the use of imputation of nonresponse. PASI 75, PASI 90, and PASI 100 responses indicate a reduction from baseline of at least 75%, at least 90%, and 100%, respectively, in the PASI score. The criteria of an IGA score of 0 (clear skin) or 1 (almost clear skin) included at least a 2-grade improvement from baseline. H denotes hypothesis, and NA not applicable because tests performed on or before week 16 are based on the total bimekizumab group.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Hypothesis tests H<sub>1</sub> and H<sub>2</sub> tested the noninferiority of bimekizumab as compared with adalimumab with respect to a PASI 90 response and an IGA score of 0 or 1, respectively, at week 16, with the use of a noninferiority margin of â10 percentage points; bimekizumab showed noninferiority as compared with adalimumab on the basis of the 95% confidence interval of the between-group difference. Hypothesis tests H<sub>3</sub> and H<sub>4</sub> tested the superiority of bimekizumab as compared with adalimumab with respect to a PASI 90 response and an IGA score of 0 or 1, respectively, at week 16.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">P&lt;0.001. P values for the comparison of treatment groups are based on the CochranâMantelâHaenszel test from the general association.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">Hypothesis tests H<sub>7</sub>, H<sub>8</sub>, and H<sub>9</sub> tested the superiority of bimekizumab as compared with adalimumab for a PASI 100 response, a PASI 90 response, and an IGA score of 0 or 1, respectively, at week 24 on the basis of the total bimekizumab group, whereas hypothesis tests H<sub>10</sub>, H<sub>11</sub>, and H<sub>12</sub> evaluated the same end points on the basis of the group receiving bimekizumab every 4 weeks.</div></div></div></figcaption></a><figcaption><div class="caption">Primary End Points and Ranked Secondary End Points.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2102388_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2102388_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2102388/asset/4fe79383-2b2d-44e0-b902-598d8736e494/assets/images/large/nejmoa2102388_t3.jpg" height="2896" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1" data-xml-valign="top"><th class="txlx-borders hanging02" data-xml-align="left">Event</th><th class="txxx-borders" colspan="3"><span>Weeks 0â24<a href="#core-t3fn2" role="doc-noteref">â </a></span></th><th class="txxr-borders" colspan="3"><span>Weeks 24â56<a href="#core-t3fn3" role="doc-noteref">â¡</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders hanging02">&nbsp;</td><th class="xxxx-borders">Bimekizumab Every 4 Wk<br>(N=158)</th><th class="xxxx-borders">Bimekizumab Every 4 Wkâ<br>Every 8 Wk<br>(N=161)</th><th class="xxxx-borders">Adalimumab<br>(N=159)</th><th class="xxxx-borders">Bimekizumab Every 4 Wk<br>(N=152)</th><th class="xxxx-borders">Bimekizumab Every 4 Wkâ<br>Every 8 Wk<br>(N=149)</th><th class="xxxr-borders">Adalimumabâ<br>Bimekizumab Every 4 Wk<br> (N=149)</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders hanging02">&nbsp;</td><th class="xxxr-borders" colspan="6"><span>number (percent)</span></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Overview</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any adverse event</td><td class="xxxx-borders">112 (70.9)</td><td class="xxxx-borders">116 (72.0)</td><td class="xxxx-borders">111 (69.8)</td><td class="xxxx-borders">101 (66.4)</td><td class="xxxx-borders">104 (69.8)</td><td class="xxxr-borders">111 (74.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders shading">4 (2.5)</td><td class="xxxx-borders shading">1 (0.6)</td><td class="xxxx-borders shading">5 (3.1)</td><td class="xxxx-borders shading">2 (1.3)</td><td class="xxxx-borders shading">8 (5.4)</td><td class="xxxr-borders shading">9 (6.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Discontinuation due to adverse event</td><td class="xxxx-borders">3 (1.9)</td><td class="xxxx-borders">6 (3.7)</td><td class="xxxx-borders">5 (3.1)</td><td class="xxxx-borders">3 (2.0)</td><td class="xxxx-borders">2 (1.3)</td><td class="xxxr-borders">5 (3.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Drug-related adverse event</td><td class="xxxx-borders shading">41 (25.9)</td><td class="xxxx-borders shading">46 (28.6)</td><td class="xxxx-borders shading">38 (23.9)</td><td class="xxxx-borders shading">40 (26.3)</td><td class="xxxx-borders shading">35 (23.5)</td><td class="xxxr-borders shading">45 (30.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Severe adverse event</td><td class="xxxx-borders">3 (1.9)</td><td class="xxxx-borders">2 (1.2)</td><td class="xxxx-borders">5 (3.1)</td><td class="xxxx-borders">5 (3.3)</td><td class="xxxx-borders">8 (5.4)</td><td class="xxxr-borders">7 (4.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.6)<a href="#core-t3fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Most common adverse events</b><a href="#core-t3fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Upper respiratory tract infection<a href="#core-t3fn6" role="doc-noteref">â</a></td><td class="xxxx-borders shading">48 (30.4)</td><td class="xxxx-borders shading">45 (28.0)</td><td class="xxxx-borders shading">55 (34.6)</td><td class="xxxx-borders shading">36 (23.7)</td><td class="xxxx-borders shading">36 (24.2)</td><td class="xxxr-borders shading">42 (28.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Oral candidiasis</td><td class="xxxx-borders">15 (9.5)</td><td class="xxxx-borders">19 (11.8)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">20 (13.2)</td><td class="xxxx-borders">13 (8.7)</td><td class="xxxr-borders">26 (17.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">6 (3.8)</td><td class="xxxx-borders shading">9 (5.6)</td><td class="xxxx-borders shading">13 (8.2)</td><td class="xxxx-borders shading">2 (1.3)</td><td class="xxxx-borders shading">3 (2.0)</td><td class="xxxr-borders shading">3 (2.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">8 (5.1)</td><td class="xxxx-borders">5 (3.1)</td><td class="xxxx-borders">4 (2.5)</td><td class="xxxx-borders">2 (1.3)</td><td class="xxxx-borders">3 (2.0)</td><td class="xxxr-borders">2 (1.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Adverse events of interest</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Inflammatory bowel disease</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adjudicated suicidal ideation or behavior</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Cancer<a href="#core-t3fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">4 (2.5)</td><td class="xxxx-borders">1 (0.6)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (1.3)</td><td class="xxxr-borders">1 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">NMSC</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (1.9)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Active tuberculosis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Latent tuberculosis</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.7)</td><td class="xxxx-borders shading">3 (2.0)</td><td class="xxxr-borders shading">1 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious hypersensitivity reaction</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adjudicated MACE</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Elevated level of liver enzymes<a href="#core-t3fn8" role="doc-noteref">â â </a></td><td class="xxxx-borders">3 (1.9)</td><td class="xxxx-borders">4 (2.5)</td><td class="xxxx-borders">11 (6.9)</td><td class="xxxx-borders">1 (0.7)</td><td class="xxxx-borders">2 (1.3)</td><td class="xxxr-borders">6 (4.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Serious infection<a href="#core-t3fn9" role="doc-noteref">â¡â¡</a></td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">1 (0.6)</td><td class="xbxx-borders shading">1 (0.6)</td><td class="xbxx-borders shading">1 (0.7)</td><td class="xbxx-borders shading">2 (1.3)</td><td class="xbxr-borders shading">4 (2.7)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Data shown are adverse events with an onset on or after the first dose of trial treatment and up to 140 days after the final dose. MACE denotes major adverse cardiovascular event, and NMSC nonmelanoma skin cancer.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Data for weeks 0 to 24 include all the patients who received at least one dose of bimekizumab or adalimumab (full safety set).</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">Data for weeks 24 to 56 include all the patients who had received at least one dose of bimekizumab at week 24 or beyond (bimekizumab week-24 set).</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">A 50-year-old male patient received a diagnosis of squamous-cell carcinoma of the tongue 6 weeks after the start of adalimumab treatment and died 5 months later. Mouth ulcerations were noted on screening; he had no history of tobacco use.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">Shown are adverse events that occurred in more than 5% of the patients in any treatment group from weeks 0 to 24 or from weeks 24 to 56.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="core-t3fn6" role="paragraph" data-to-manipulate="true">Upper respiratory tract infections included nasopharyngitis, upper respiratory tract infection, pharyngitis, rhinitis, tonsillitis, sinusitis, acute sinusitis, chronic sinusitis, laryngitis, peritonsillar abscess, and sinobronchitis.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t3fn7" role="paragraph" data-to-manipulate="true">From weeks 0 to 24, three cases of basal-cell carcinoma and one case of anal squamous-cell carcinoma were reported in the group receiving bimekizumab every 4 weeks and then every 8 weeks, and one case of squamous-cell carcinoma of the tongue was reported in the group receiving adalimumab. From weeks 24 to 56, one case each of colon cancer and squamous-cell carcinoma was reported in the group receiving bimekizumab every 4 weeks and then every 8 weeks, and one case of basal-cell carcinoma was reported in the group that switched from adalimumab to bimekizumab every 4 weeks at week 24.</div></div><div role="doc-footnote" data-has="label"><div class="label">â â </div><div id="core-t3fn8" role="paragraph" data-to-manipulate="true">Liver-function tests included the following terms reported as adverse events: elevated levels of hepatic enzymes, aspartate aminotransferase, blood bilirubin, Î³-glutamyltransferase, alanine aminotransferase, or aminotransferases or increased liver-function test findings.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡â¡</div><div id="core-t3fn9" role="paragraph" data-to-manipulate="true">From weeks 0 to 24, one case of cellulitis was reported in the group receiving bimekizumab every 4 weeks and then every 8 weeks, and one case of infected dermal cyst was reported in the group receiving adalimumab. From weeks 24 to 56, one case of subcutaneous abscess was reported in the group receiving bimekizumab every 4 weeks, one case each of appendicitis and erysipelas was reported in the group receiving bimekizumab every 4 weeks and then every 8 weeks, and two cases of cellulitis and one case each of anal abscess and helicobacter infection were reported in the group that switched from adalimumab to bimekizumab every 4 weeks at week 24.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2102388_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2102388</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <em>Cochrane Database Syst Rev</em> 2020;1:CD011535-CD011535.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31917873/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000510398500041" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systemic+pharmacological+treatments+for+chronic+plaque+psoriasis%3A+a+network+meta-analysis.&amp;publication_year=2020&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD011535-CD011535&amp;pmid=31917873" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. <em>J Immunol</em> 2018;201:1605-1613.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1800013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30181299/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000443585800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Discovery+of+the+IL-23%2FIL-17+signaling+pathway+and+the+treatment+of+psoriasis.&amp;publication_year=2018&amp;journal=J+Immunol&amp;pages=1605-1613&amp;doi=10.4049%2Fjimmunol.1800013&amp;pmid=30181299" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Brembilla NC, Senra L, Boehncke W-H. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. <em>Front Immunol</em> 2018;9:1682-1682.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3389/fimmu.2018.01682" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30127781/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000440582100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+IL-17+family+of+cytokines+in+psoriasis%3A+IL-17A+and+beyond.&amp;publication_year=2018&amp;journal=Front+Immunol&amp;pages=1682-1682&amp;doi=10.3389%2Ffimmu.2018.01682&amp;pmid=30127781" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Prignano F, Choi J, Pieper B, Iversen L. Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars. <em>Expert Opin Biol Ther</em> 2021;21:75-80.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/14712598.2020.1812576" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32886008/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000566964500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anti-tumor+necrosis+factor+agents+in+psoriasis%3A+addressing+key+challenges+using+biosimilars.&amp;publication_year=2021&amp;journal=Expert+Opin+Biol+Ther&amp;pages=75-80&amp;doi=10.1080%2F14712598.2020.1812576&amp;pmid=32886008" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. <em>Ann Rheum Dis</em> 2018;77:523-532.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/annrheumdis-2017-212127" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29275332/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000429731800014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dual+IL-17A+and+IL-17F+neutralisation+by+bimekizumab+in+psoriatic+arthritis%3A+evidence+from+preclinical+experiments+and+a+randomised+placebo-controlled+clinical+trial+that+IL-17F+contributes+to+human+chronic+tissue+inflammation.&amp;publication_year=2018&amp;journal=Ann+Rheum+Dis&amp;pages=523-532&amp;doi=10.1136%2Fannrheumdis-2017-212127&amp;pmid=29275332" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Yost J, Gudjonsson JE. The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities. <em>F1000 Med Rep</em> 2009;1:30-30.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3410/M1-30" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20948750/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+role+of+TNF+inhibitors+in+psoriasis+therapy%3A+new+implications+for+associated+comorbidities.&amp;publication_year=2009&amp;journal=F1000+Med+Rep&amp;pages=30-30&amp;doi=10.3410%2FM1-30&amp;pmid=20948750" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Warren RB, See K, Burge R, et al. Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network meta-analyses. <em>Dermatol Ther (Heidelb)</em> 2020;10:73-86.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s13555-019-00337-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31686337/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000493933000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rapid+response+of+biologic+treatments+of+moderate-to-severe+plaque+psoriasis%3A+a+comprehensive+investigation+using+Bayesian+and+frequentist+network+meta-analyses.&amp;publication_year=2020&amp;journal=Dermatol+Ther+%28Heidelb%29&amp;pages=73-86&amp;doi=10.1007%2Fs13555-019-00337-y&amp;pmid=31686337" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <em>Lancet</em> 2021;397:487-498.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)00125-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33549193/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000616661900024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bimekizumab+versus+ustekinumab+for+the+treatment+of+moderate+to+severe+plaque+psoriasis+%28BE+VIVID%29%3A+efficacy+and+safety+from+a+52-week%2C+multicentre%2C+double-blind%2C+active+comparator+and+placebo+controlled+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=487-498&amp;doi=10.1016%2FS0140-6736%2821%2900125-2&amp;pmid=33549193" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] isoforms, including interleukin-17F/17F. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the interleukin-17A inhibitor secukinumab. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] defense against candida at the oral mucosa. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. <em>Br J Clin Pharmacol</em> 2017;83:991-1001.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bcp.13185" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27859546/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000401234300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-in-human+randomized+study+of+bimekizumab%2C+a+humanized+monoclonal+antibody+and+selective+dual+inhibitor+of+IL-17A+and+IL-17F%2C+in+mild+psoriasis.&amp;publication_year=2017&amp;journal=Br+J+Clin+Pharmacol&amp;pages=991-1001&amp;doi=10.1111%2Fbcp.13185&amp;pmid=27859546" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. <em>Lancet</em> 2021;397:475-486.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)00126-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33549192/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000616661900023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bimekizumab+efficacy+and+safety+in+moderate+to+severe+plaque+psoriasis+%28BE+READY%29%3A+a+multicentre%2C+double-blind%2C+placebo-controlled%2C+randomised+withdrawal+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=475-486&amp;doi=10.1016%2FS0140-6736%2821%2900126-4&amp;pmid=33549192" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the interleukin-17A inhibitor secukinumab. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] defense against candida at the oral mucosa. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. <em>N Engl J Med</em> 2021;384:142-152.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_12_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2102388&amp;key=10.1056%2FNEJMoa2102383&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000643851000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bimekizumab+versus+secukinumab+in+plaque+psoriasis.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=142-152&amp;doi=10.1056%2FNEJMoa2102383" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the interleukin-17A inhibitor secukinumab. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] defense against candida at the oral mucosa. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <em>J Am Acad Dermatol</em> 2018;79(2):277.e10-286.e10.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2018.03.037" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29609013/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000438603100023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dual+neutralization+of+both+interleukin+17A+and+interleukin+17F+with+bimekizumab+in+patients+with+psoriasis%3A+results+from+BE+ABLE+1%2C+a+12-week+randomized%2C+double-blinded%2C+placebo-controlled+phase+2b+trial.&amp;publication_year=2018&amp;journal=J+Am+Acad+Dermatol&amp;pages=277.e10-286.e10&amp;doi=10.1016%2Fj.jaad.2018.03.037&amp;pmid=29609013" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <em>J Am Acad Dermatol</em> 2017;76:405-417.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2016.11.041" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28057360/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000402797000057" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+guselkumab%2C+an+anti-interleukin-23+monoclonal+antibody%2C+compared+with+adalimumab+for+the+continuous+treatment+of+patients+with+moderate+to+severe+psoriasis%3A+results+from+the+phase+III%2C+double-blinded%2C+placebo-+and+active+comparator-controlled+VOYAGE+1+trial.&amp;publication_year=2017&amp;journal=J+Am+Acad+Dermatol&amp;pages=405-417&amp;doi=10.1016%2Fj.jaad.2016.11.041&amp;pmid=28057360" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. <em>J Am Acad Dermatol</em> 2017;76:418-431.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2016.11.042" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28057361/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000402797000058" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+guselkumab%2C+an+anti-interleukin-23+monoclonal+antibody%2C+compared+with+adalimumab+for+the+treatment+of+patients+with+moderate+to+severe+psoriasis+with+randomized+withdrawal+and+retreatment%3A+results+from+the+phase+III%2C+double-blind%2C+placebo-+and+active+comparator-controlled+VOYAGE+2+trial.&amp;publication_year=2017&amp;journal=J+Am+Acad+Dermatol&amp;pages=418-431&amp;doi=10.1016%2Fj.jaad.2016.11.042&amp;pmid=28057361" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 23, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2102383" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Bimekizumab versus Secukinumab in Plaque Psoriasis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">K. Reich and Others</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 15, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2113092" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Bimekizumab versus Adalimumab in Plaque Psoriasis</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Graduate Training / Residency</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/509002/full-time-advanced-lung-disease-and-transplantation-clinical-research-fellow-/?query=fjwp&amp;rid=3059">Full-Time Advanced Lung Disease and Transplantation Clinical Research Fellow </a></div></div><div class="nejm-widget_item"><div><span> Binghamton, New York</span></div><div><span>Otolaryngology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887506/otolaryngology-200k-loan-repayment-guthrie-lourdes/?query=fjwp&amp;rid=899">Otolaryngology - $200K Loan Repayment - Guthrie Lourdes</a></div></div><div class="nejm-widget_item"><div><span> Eugene, Oregon</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886316/family-medicine-physician-without-ob/?query=fjwf&amp;rid=14710">Family Medicine Physician without OB</a></div></div><div class="nejm-widget_item"><div><span> Cleveland, Ohio</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/884878/regional-hematology-and-medical-oncology-physicians/?query=fjwf&amp;rid=2201">Regional Hematology and Medical Oncology Physicians</a></div></div><div class="nejm-widget_item"><div><span> Manchester, Connecticut</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879689/primary-care-physician/?query=fjwf&amp;rid=33464">Primary Care Physician</a></div></div><div class="nejm-widget_item"><div><span> Danville, Pennsylvania</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881483/pediatric-radiologist-onsite-or-hybrid-options-140k-incentive-package/?query=fjwf&amp;rid=764">Pediatric Radiologist; Onsite or Hybrid Options; $140k Incentive Package</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2102388&amp;pubId=41290213&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d68ba925aef18e-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d68ba925aef18e-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d68ba925aef18e-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$658988142$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$658988142$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$658988142$--></div></div><div class="mlt-body"><!--?lit$658988142$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$658988142$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$658988142$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$658988142$-->Feb 08, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2314345?query=recirc_Semantic" target="_self">Psoriasis â More Progress but More Questions</a></div><div class="mlt-article-authors"><!--?lit$658988142$-->J.M. Gelfand</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$658988142$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$658988142$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$658988142$-->Apr 01, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2022516?query=recirc_Semantic" target="_self">Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis</a></div><div class="mlt-article-authors"><!--?lit$658988142$-->I.B. McInnes and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$658988142$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$658988142$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$658988142$-->Feb 08, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2308713?query=recirc_Semantic" target="_self">An Oral Interleukin-23âReceptor Antagonist Peptide for Plaque Psoriasis</a></div><div class="mlt-article-authors"><!--?lit$658988142$-->R. Bissonnette and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$658988142$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$658988142$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$658988142$-->Sep 30, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra1907607?query=recirc_Semantic" target="_self">Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease</a></div><div class="mlt-article-authors"><!--?lit$658988142$-->D.C. Baumgart and C. Le Berre</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$658988142$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$658988142$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$658988142$-->Aug 01, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2312302?query=recirc_Semantic" target="_self">Brief Report: Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease</a></div><div class="mlt-article-authors"><!--?lit$658988142$-->H. Griffin and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2102388?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2102388" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2102388.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2102388"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Bimekizumab versus Adalimumab in Plaque Psoriasis</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2026983" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Randomized Trial of Fetal Surgery for Moderate Left Diaphragmatic Hernia</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2102383" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Bimekizumab versus Secukinumab in Plaque Psoriasis</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f0.jpg"><img src="/cms/10.1056/NEJMoa2102388/asset/d986ea30-c4c8-4e55-84b1-561a5256a379/assets/images/large/nejmoa2102388_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f1.jpg"><img src="/cms/10.1056/NEJMoa2102388/asset/1fd65748-27d0-48b4-9790-f97eebe8312c/assets/images/large/nejmoa2102388_f1.jpg" height="3038" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption>Screening, Randomization, and Follow-up to Week 56.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2102388_f2.jpg"><img src="/cms/10.1056/NEJMoa2102388/asset/cb32140f-4c58-4b60-b17b-e1b2e42c2bd3/assets/images/large/nejmoa2102388_f2.jpg" height="2875" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Clinical Efficacy According to Treatment Group through 56 Weeks.</div><div class="notes"><div role="doc-footnote">Data are shown for the intention-to-treat population, which includes all the patients who underwent randomization. Percentages were calculated with the use of imputation of nonresponse. Scores on the Psoriasis Area and Severity Index (PASI) range from 0 to 72, with higher scores indicating worse disease. PASI 75, PASI 90, and PASI 100 responses indicate a reduction from baseline of at least 75%, at least 90%, and 100%, respectively, in the PASI score. Scores on the Investigatorâs Global Assessment (IGA) range from 0 (indicating clear skin) to 4 (indicating severe psoriasis). The criteria of an IGA score of 0 (clear skin) or 1 (almost clear skin) included at least a 2-grade improvement from baseline.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary End Points and Ranked Secondary End Points.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/385/2" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 385 No. 2</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 08, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2027030" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Randomized Trial of Fetal Surgery for Severe Left Diaphragmatic Hernia</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.A. Deprest and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 08, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2026983" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Randomized Trial of Fetal Surgery for Moderate Left Diaphragmatic Hernia</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.A. Deprest and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/review-article" class="issue-item_type">Review Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 08, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMra1604481" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Hematuria in Adults</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.R. Ingelfinger</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2102388%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2102388&amp;pubId=41290213&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2102388%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2102388&amp;pubId=41290213&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright Â© 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id06048247709576261" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d68ba925aef18e-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d68ba925aef18e-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d68ba925aef18e-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d68ba925aef18e-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d68ba925aef18e-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d68ba925aef18e-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d68ba925aef18e-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d68ba925aef18e-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d68ba925aef18e-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d68ba925aef18e-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d68ba91eb2f18e',t:'MTc0OTUzNDE0OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d68ba91eb2f18e&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">â</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">Moreâ¦</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><phj-uwufvusdvzzv></phj-uwufvusdvzzv><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2102388?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-transactionid="mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" id="captureIFrame_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" target="captureIFrame_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="â" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" name="capture_screen"><input id="capture_signIn_js_version_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" name="js_version"><input id="capture_signIn_transactionId_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-capturefield="undefined" value="mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" type="hidden" class="capture_transactionId_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" name="capture_transactionId"><input id="capture_signIn_form_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" name="form"><input id="capture_signIn_flow_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" name="flow"><input id="capture_signIn_client_id_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" name="client_id"><input id="capture_signIn_redirect_uri_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" name="redirect_uri"><input id="capture_signIn_response_type_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" name="response_type"><input id="capture_signIn_flow_version_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" name="flow_version"><input id="capture_signIn_settings_version_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" name="settings_version"><input id="capture_signIn_locale_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" name="locale"><input id="capture_signIn_recaptcha_version_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_mqjo042ct473ipfzlpd56wj87j9fr8gkyt5gmhry" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>